

ALECENSA CAN DELIVER FOR PATIENTS



"It's the little things for me.
For instance, my cherished ritual is doing the morning crossword with my husband. With our busy lives, sometimes it's the only time we get to spend together."

HELEN, 56

| Helen's select characteristics | Patients in the ALEX ITT population ² |
|--------------------------------|--|
| ECOG PS 1 | 186 (61%) |
| Nonsmoker | 188 (62%) |
| No CNS metastases | 181 (60%) |
| Asian | 138 (46%) |

Hypothetical patient case studies.



"I love my weekly phone chats with my granddaughter—it's how we bond. I want to be able to continue these conversations for as long as I can."

SANDRA, 71

| Sandra's select characteristics | Patients in the ALEX ITT population ² |
|---------------------------------|--|
| ECOG PS 1 | 186 (61%) |
| Former smoker | 98 (32%) |
| CNS metastases | 122 (40%) |
| Prior brain radiation | 47 (16%) |



"Because of my medical history, I want my doctor to look at the full picture when deciding on a treatment that's right for me."

GAVIN, 38

| Gavin's select characteristics | Patients in the ALEX ITT population ² |
|--------------------------------|--|
| ECOG PS 0 | 97 (32%) |
| Nonsmoker | 188 (62%) |
| ≤3 sites of metastases | 71 (23%) |
| No liver involvement | 233 (77%) |
| Diagnosed with depression | 7 (5%) |



National Comprehensive Cancer Network® (NCCN®) recommends alectinib (ALECENSA) for ALK+ NSCLC³

- As a first-line treatment option for metastatic disease (NCCN Category 1, Preferred)^b
- As an adjuvant treatment option for patients with completely resected tumors ≥4 cm or who are node positive (Category 1)^c

^a The initial FDA approval for ALECENSA was in 2015.

^bWhen an ALK rearrangement is discovered prior to first-line systemic therapy.

^cThe NCCN Guidelines for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques, but do not endorse any specific commercially available biomarker assays or commercial laboratories.

ALK=anaplastic lymphoma kinase; CNS=central nervous system; ECOG PS=Eastern Cooperative Oncology performance status; FDA=US Food and Drug Administration; ITT=intent-to-treat; mNSCLC=metastatic non-small cell lung cancer.

Indications

ALECENSA is a kinase inhibitor indicated for:

- treatment of adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test
- adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥4 cm or node positive), as detected by an FDA-approved test

Select Important Safety Information

The Warnings and Precautions for ALECENSA include:


- Hepatotoxicity
- Interstitial Lung Disease (ILD)/Pneumonitis
- Renal Impairment
- Bradycardia
- Severe Myalgia and Creatine Phosphokinase (CPK) Elevation
- Hemolytic Anemia
- Embryo-Fetal Toxicity

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.



ALEX clinical trial design

A global, open-label, Phase 3 trial in 1L patients with ALK+ mNSCLC^{1,4}



^aPatients were required to have an ECOG PS of 0-2 and ALK+ NSCLC as identified by the VENTANA ALK (D5F3) CDx assay.¹

^bRandomization was stratified by ECOG PS (0/1 vs 2), race (Asian and other races), CNS metastases at baseline (yes vs no). Stratification factors were applied to hazard ratio and *P*-value analysis.¹

Studied across multiple endpoints¹

Primary

- PFS (INV)

Additional

- PFS (IRC)
- Time to CNS progression (IRC)
- ORR (IRC)
- DOR (IRC)
- OS (INV)

Exploratory

- CNS ORR in patients with CNS metastasis at baseline (IRC)
- CNS DOR in patients with CNS metastasis at baseline (IRC)

1L=first line; DOR=duration of response; INV=investigator; IRC=independent review committee; ORR=objective response rate; OS=overall survival; PFS=progression-free survival.

Select Important Safety Information

Hepatotoxicity

- Hepatotoxicity occurred in 41% of 533 patients treated with ALECENSA and the incidence of Grade ≥ 3 hepatotoxicity was 8%. In the ALINA study, hepatotoxicity occurred in 61% of patients treated with ALECENSA and the incidence of Grade ≥ 3 hepatotoxicity was 4.7%. The majority (72% of 136 patients) of elevated transaminases occurred during the first 3 months of treatment. Treatment discontinuation due to hepatotoxicity occurred in 3.6% of patients who received ALECENSA in the pooled safety population and 1.6% of patients treated in the ALINA study

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.



Baseline characteristics were well-balanced between treatment arms^{2,4}

| Baseline characteristics in ITT population | ALECENSA (n=152) | crizotinib (n=151) |
|--|------------------|--------------------|
| Age, years | | |
| Median | 58 (25-88) | 54 (18-91) |
| Sex, n (%) | | |
| Female | 84 (55%) | 87 (58%) |
| Male | 68 (45%) | 64 (42%) |
| Race, n (%) | | |
| Asian | 69 (45%) | 69 (46%) |
| Black | 0 | 4 (3%) |
| Native Hawaiian or other Pacific Islander | 1 (1%) | 1 (1%) |
| White | 76 (50%) | 75 (50%) |
| Unknown | 2 (1%) | 2 (1%) |
| Ethnicity, n (%) | | |
| Hispanic or Latino | 8 (5%) | 8 (5%) |
| Not Hispanic or Latino | 138 (91%) | 136 (90%) |
| Not stated | 6 (4%) | 7 (5%) |
| Smoking status, n (%) | | |
| Nonsmoker | 92 (61%) | 98 (65%) |
| Smoker | 60 (40%) | 53 (35%) |
| ECOG PS, n (%) | | |
| 0 or 1 | 142 (93%) | 141 (93%) |
| 2 | 10 (7%) | 10 (7%) |
| Disease stage, n (%) | | |
| Stage IV | 148 (97%) | 145 (96%) |
| Histological classification, n (%) | | |
| Adenocarcinoma | 137 (90%) | 142 (94%) |
| Squamous-cell carcinoma | 5 (3%) | 2 (1%) |
| Other | 10 (7%) | 7 (5%) |

| Baseline characteristics in ITT population (cont'd) | ALECENSA (n=152) | crizotinib (n=151) |
|---|------------------|--------------------|
| CNS metastases at baseline, n (%) | | |
| Yes | 64 (42%) | 58 (38%) |
| No | 88 (58%) | 93 (62%) |
| Prior CNS radiation, n (%) | | |
| Yes | 26 (17%) | 21 (14%) |
| No | 126 (83%) | 130 (86%) |
| Prior treatment for CNS metastases, n (%) | n=27 | n=22 |
| Brain surgery | 1 (4%) | 1 (5%) |
| Radiosurgery | 5 (19%) | 4 (18%) |
| Whole-brain radiotherapy | 17 (63%) | 16 (73%) |
| Other | 4 (15%) | 1 (5%) |
| Number of lesions, n (%) | | |
| 1-3 | 37 (24%) | 34 (23%) |
| >3 | 115 (76%) | 117 (76%) |
| Site of metastases, n (%) | | |
| Liver | 30 (20%) | 40 (27%) |
| Concurrent psychiatric disorders, n (%) | | |
| Insomnia | 13 (9%) | 10 (7%) |
| Anxiety | 7 (5%) | 10 (7%) |
| Depression | 3 (2%) | 4 (3%) |
| Other ^a | 2 (1%) | 7 (5%) |

Almost half of patients in the ALECENSA treatment arm and about 1/3 of patients on crizotinib had CNS metastasis at baseline

^aIncludes sleep disorder, adjustment disorder, anxiety disorder, confusional state, disorientation, drug dependence, mental status changes, and psychotic disorder.

ALEX included patients with a broad range of characteristics, such as >3 lesions and liver metastases

Select Important Safety Information

Hepatotoxicity (cont'd)

- Concurrent elevations in alanine transaminase (ALT) or aspartate transaminase (AST) greater than or equal to 3 times the ULN and total bilirubin greater than or equal to 2 times the ULN, with normal alkaline phosphatase, occurred in less than 1% of patients treated with ALECENSA. Three patients with Grades 3-4 AST/ALT elevations had drug-induced liver injury (documented by liver biopsy in 2 cases)

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.



In ALK+ mNSCLC (primary analysis):

ALECENSA delivered superior mPFS vs crizotinib¹


Primary analysis

- PFS by IRC: In the ITT population, **mPFS was 25.7 months for ALECENSA** (95% CI: 19.9, NE) compared with 10.4 months with crizotinib (95% CI: 7.7, 14.6); (HR=0.53 [95% CI: 0.38, 0.73]; $P<0.0001$)^{1ab}
 - Patients with event: 41% with ALECENSA (n=63/152); 61% with crizotinib (n=92/151)
- Median duration of follow-up: ALECENSA 18.6 months (range: 0.5-29.0 months); crizotinib 17.6 months (range: 0.3-27.0 months)⁴

Follow-up analysis | INV-assessed

- Median duration of follow-up: ALECENSA 27.8 months (range: 0.5-38.7 months); crizotinib 22.8 months (range: 0.3-36.7 months)⁵

The follow-up analysis was performed when approximately 50% of patients in the ALECENSA arm experienced a PFS event and was conducted for the purpose of obtaining a median estimate of PFS. No formal treatment comparisons were performed for the follow-up analysis.²



Number at risk

| | | | | | | | | | | | | | |
|-------------------|-----|-----|-----|-----|----|----|----|----|----|----|----|----|---|
| ALECENSA | 152 | 135 | 113 | 109 | 99 | 84 | 81 | 81 | 77 | 69 | 33 | 19 | 4 |
| crizotinib | 151 | 132 | 104 | 83 | 64 | 47 | 42 | 35 | 31 | 24 | 10 | 8 | |

^aStratified by race (Asian vs non-Asian) and CNS metastases at baseline (yes vs no) for Cox model, log-rank test, and Cochran-Mantel-Haenszel test, respectively.

^bResults for PFS as determined by INV assessment (HR=0.48; 95% CI, 0.35-0.66; $P<0.0001$) were similar to that observed by IRC.

CI=confidence interval; HR=hazard ratio; mPFS=median progression-free survival; NE=not estimable.

Select Important Safety Information

Hepatotoxicity (cont'd)

- Monitor liver function tests including ALT, AST, and total bilirubin every 2 weeks during the first 3 months of treatment, then once a month and as clinically indicated, with more frequent testing in patients who develop transaminase and bilirubin elevations. Based on the severity of the adverse drug reaction, withhold ALECENSA and resume at a reduced dose, or permanently discontinue ALECENSA

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.




Observed in prespecified exploratory analyses:

Consistent PFS benefit with ALECENSA was observed across a variety of patient types⁴

Primary analysis

Exploratory subgroup analysis (investigator)⁴



All exploratory analyses are descriptive in nature. Subgroups were not powered to show differences between treatment arms. Hazard ratios were estimated from unstratified analyses.⁶

Adapted from *The New England Journal of Medicine*, Peters S, Camidge DR, Shaw AT, et al, Alectinib versus crizotinib in untreated *ALK*-positive non-small-cell lung cancer, Vol 377, 829-838. Copyright © 2017 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

Select Important Safety Information

Interstitial Lung Disease (ILD)/Pneumonitis

- ILD/pneumonitis occurred in 1.3% of 533 patients treated with ALECENSA with 0.4% of patients experiencing Grade 3 ILD/pneumonitis. Five patients (0.9%) discontinued ALECENSA due to ILD/pneumonitis. The median time-to-onset of Grade 3 or higher ILD/pneumonitis was 2.1 months (range: 0.6 months to 3.6 months)

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.



SURVIVAL
AND TUMOR
RESPONSE

Observed in an exploratory analysis:


ALECENSA is the only TKI for ALK+ mNSCLC with 5-year OS data²

OS data were not mature at the time of primary cutoff and the median has still not been reached.^{1,2,7}

Exploratory analysis

This post-hoc OS analysis, conducted at ~5 years after randomization of the last patient, was exploratory in nature, and was not powered to show statistical significance.^{2,7}

- The exploratory landmark analysis included subgroups of patients with brain metastases (HR=0.62 [95% CI: 0.36, 1.05]) and without brain metastases at baseline (HR=0.79 [95% CI: 0.48, 1.3])^{2,7}



| Number at risk | |
|----------------|--|
| ALECENSA | 152 131 120 103 94 88 81 81 78 75 71 50 16 |
| crizotinib | 151 128 104 93 73 67 60 55 50 48 45 28 9 |

TKI=tyrosine kinase inhibitor.

Select Important Safety Information

Interstitial Lung Disease (ILD)/Pneumonitis (cont'd)


- Promptly investigate for ILD/pneumonitis in any patient who presents with worsening of respiratory symptoms indicative of ILD/pneumonitis (eg, dyspnea, cough, and fever)

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.




SURVIVAL
AND TUMOR
RESPONSE

13% of patients on ALECENSA achieved complete response¹



Most patients on ALECENSA achieved a DOR lasting greater than 6 months¹



^aClopper and Pearson exact binomial 95% CI.

^bStratified by race (Asian vs other) and CNS metastases at baseline (yes vs no) for Cox model, log-rank test, and Cochran-Mantel-Haenszel test, respectively.

CR=complete response; DOR=duration of response; ORR=overall response rate; PR=partial response.

Select Important Safety Information

Interstitial Lung Disease (ILD)/Pneumonitis (cont'd)

- Immediately withhold ALECENSA treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue ALECENSA if no other potential causes of ILD/pneumonitis have been identified

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.




Observed in prespecified exploratory subgroup analyses:

Reduction in risk of progression or death for patients with CNS metastasis at baseline with ALECENSA⁸

Prespecified exploratory subgroup analysis

Patients with CNS metastasis at baseline

Patients without CNS metastasis at baseline



Number at Risk

| | | | | | | | | | | |
|------------|----|----|----|----|----|----|----|----|---|---|
| ALECENSA | 64 | 54 | 41 | 39 | 36 | 31 | 24 | 10 | 4 | 1 |
| crizotinib | 58 | 48 | 66 | 22 | 17 | 9 | 6 | 3 | 1 | |

NR=not reached.

Select Important Safety Information

Renal Impairment

- Renal impairment occurred in 12% of 533 patients treated with ALECENSA, including Grade ≥ 3 in 1.7% of patients, of which 0.4% were fatal events
- The median time to Grade ≥ 3 renal impairment was 3.7 months (range 0.5 to 31.8 months). Dosage modifications for renal impairment were required in 2.4% of patients
- Permanently discontinue ALECENSA for Grade 4 renal toxicity. Withhold ALECENSA for Grade 3 renal toxicity until recovery to less than or equal to 1.5 times ULN, then resume at reduced dose

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.

Follow-up exploratory analysis (10 months later) | PFS by investigator

- Patients with CNS metastasis at baseline: **27.7 months with ALECENSA** (95% CI: 9.2, NE) vs **7.4 months with crizotinib** (95% CI: 6.6-9.6); HR=0.35 (95% CI: 0.22, 0.56)⁵
- Patients without CNS metastasis at baseline: **34.8 months with ALECENSA** (95% CI: 22.4, NE) vs **14.7 months with crizotinib** (95% CI: 10.8, 20.3); HR=0.47 (95% CI: 0.32, 0.71)⁵


All exploratory analyses are descriptive in nature. Subgroups were not powered to show differences between treatment arms. Hazard ratios were estimated from unstratified analyses.



Observed in prespecified exploratory subgroup analyses:

Reduction in risk of progression or death for patients with CNS metastasis at baseline with ALECENSA⁸

Prespecified exploratory subgroup analysis



| Number at Risk | | Day 1 | 3 | 6 | 9 | 12 | 15 | 18 | 21 | 24 | 27 | 30 |
|----------------|----|-------|----|----|----|----|----|----|----|----|----|----|
| ALECENSA | 88 | 81 | 72 | 70 | 61 | 50 | 43 | 25 | 11 | 2 | | |
| crizotinib | 93 | 84 | 71 | 62 | 48 | 37 | 29 | 13 | 4 | | | |

NR=not reached.

Select Important Safety Information

Renal Impairment

- Renal impairment occurred in 12% of 533 patients treated with ALECENSA, including Grade ≥ 3 in 1.7% of patients, of which 0.4% were fatal events
- The median time to Grade ≥ 3 renal impairment was 3.7 months (range 0.5 to 31.8 months). Dosage modifications for renal impairment were required in 2.4% of patients
- Permanently discontinue ALECENSA for Grade 4 renal toxicity. Withhold ALECENSA for Grade 3 renal toxicity until recovery to less than or equal to 1.5 times ULN, then resume at reduced dose

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.

Follow-up exploratory analysis (10 months later) | PFS by investigator

- Patients with CNS metastasis at baseline: **27.7 months with ALECENSA** (95% CI: 9.2, NE) vs **7.4 months with crizotinib** (95% CI: 6.6-9.6); HR=0.35 (95% CI: 0.22, 0.56)⁵
- Patients without CNS metastasis at baseline: **34.8 months with ALECENSA** (95% CI: 22.4, NE) vs **14.7 months with crizotinib** (95% CI: 10.8, 20.3); HR=0.47 (95% CI: 0.32, 0.71)⁵

All exploratory analyses are descriptive in nature. Subgroups were not powered to show differences between treatment arms. Hazard ratios were estimated from unstratified analyses.



ALECENSA was effective in delaying CNS metastases¹

Primary analysis

Nearly 90% of patients had no CNS involvement at first progression with ALECENSA¹

- Patients with ALK+ mNSCLC are more likely to experience brain metastases⁴
- The efficacy of ALECENSA was evaluated in delaying tumors from spreading to or growing in the CNS as the first site of progression alone or with concurrent systemic progression (time to cause-specific CNS progression)^{1,2,4}
 - This analysis was conducted to separate the effect of ALECENSA on CNS progression from systemic progression or death⁹
 - Patients who first progressed systemically, and patients with death prior to CNS or systemic progression (ALECENSA n=47; crizotinib n=42)^a were not included as events⁹

^aSystemic progression without prior CNS progression (ALECENSA n=36; crizotinib n=33); death prior to CNS or systemic progression (ALECENSA n=11; crizotinib n=9).²

^bCause-specific HR and 95% CI were estimated by Cox model where patients with competing events (systemic progression and death prior to CNS or systemic progression) were censored at the time of these events. *P*-values were estimated from two-sided, stratified, cause-specific log-rank tests.⁹

ALECENSA reduced the risk of CNS metastases vs crizotinib | IRC^{1,2}

84% REDUCTION
IN RISK


of tumors spreading to or growing in the CNS as the first site of progression (HR=0.16 [95% CI: 0.10, 0.28]; *P*<0.0001)⁹

NEARLY
4X MORE
PATIENTS

had CNS as the first site of progression with crizotinib than with ALECENSA
45% (n=68/151) with crizotinib vs
12% (n=18/152) with ALECENSA

Exploratory analysis

81% of patients achieved CNS response with ALECENSA | IRC¹



- Of the patients who achieved a CNS response, 59% experienced a CNS response that lasted for a year or more with ALECENSA vs 36% with crizotinib¹

All exploratory analyses are descriptive in nature. Subgroups were not powered to show differences between treatment arms.⁶

Select Important Safety Information

Bradycardia

- Bradycardia occurred in 11% of 533 patients treated with ALECENSA. Twenty percent of 521 patients for whom serial electrocardiograms (ECGs) were available had post-dose heart rates of less than 50 beats per minute (bpm)
- Monitor heart rate and blood pressure regularly. For asymptomatic bradycardia, dose modification is not required. For symptomatic bradycardia that is not life-threatening, withhold ALECENSA until recovery to asymptomatic bradycardia or to a heart rate ≥ 60 bpm and evaluate concomitant medications known to cause bradycardia, as well as anti-hypertensive medications. If bradycardia is attributable to a concomitant medication, resume ALECENSA at a reduced dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥ 60 bpm, with frequent monitoring as clinically indicated
- Permanently discontinue ALECENSA in cases of life-threatening bradycardia if no contributing concomitant medication is identified or for recurrence of life-threatening bradycardia

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.



ALECENSA: ALK+ treatment with a well-established safety profile¹

Primary analysis

Adverse drug reactions (>10% for all NCI CTCAE Grades or ≥2% for Grades 3-4) in patients treated with ALECENSA in ALEX¹

| Adverse reaction | ALECENSA (n=152) | | crizotinib (n=151) | |
|-------------------------------|---------------------|-------------------|-----------------------|------------|
| | All Grades | Grades 3-4 | All Grades | Grades 3-4 |
| Constipation | 34% | 0% | 33% | 0% |
| Fatigue ^a | 26% | 1.3% | 23% | 0.7% |
| Myalgia ^b | 23% | 0% | 4% | 0% |
| Edema ^c | 22% | 0.7% | 34% | 0.7% |
| Rash ^d | 15% | 0.7% | 13% | 0% |
| Nausea | 14% | 0.7% | 48% | 3.3% |
| Renal Impairment ^e | 12% | 3.9% ^g | 0% | 0% |
| Diarrhea | 12% | 0% | 45% | 2% |
| Bradycardia ^f | 11% | 0% | 15% | 0% |

- Safety results at 5 years post-hoc analysis were consistent with the originally reported adverse reactions of ALECENSA in ALEX⁷
 - Constipation (38.2%), anemia (27.6%), fatigue (22.4%), and increased blood bilirubin (22.4%) were the most common adverse events (≥20%) at 5 years of follow-up²
 - No new safety signals observed after up to 5 years of follow-up¹⁰

^aIncludes fatigue and asthenia.

^bIncludes myalgia and musculoskeletal pain.

^cIncludes peripheral edema, edema, eyelid edema, localized edema, and face edema.

^dIncludes rash, rash maculo-papular, dermatitis acneiform, erythema, generalized rash, rash macular, rash papular, exfoliative rash, and pruritic rash.

^eIncludes increased blood creatinine, creatinine renal clearance decreased, glomerular filtration rate decreased, and acute kidney injury.

^fIncludes reported cases of bradycardia and sinus bradycardia but is not based on serial ECG assessment.

^gIncludes 2 Grade 5 events.

ECG=electrocardiogram; NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events.



Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.

Laboratory abnormalities

Primary analysis

Laboratory abnormalities occurring in >10% of patients treated with ALECENSA or crizotinib^{1a}

| Parameter | ALECENSA (n=152) | | crizotinib (n=151) | |
|--------------------------------------|------------------|------------|--------------------|------------|
| | All Grades | Grades 3-4 | All Grades | Grades 3-4 |
| Chemistry | | | | |
| Hyperbilirubinemia | 54% | 5% | 4.7% | 0% |
| Increased AST | 50% | 6% | 56% | 11% |
| Increased alkaline phosphatase | 50% | 0% | 44% | 0% |
| Increased ALT | 40% | 6% | 62% | 16% |
| Increased creatinine | 38% | 4.1% | 23% | 0.7% |
| Increased CPK | 37% | 2.8% | 52% | 1.4% |
| Hypocalcemia | 29% | 0% | 61% | 1.4% |
| Hyperglycemia | 22% | 2.2% | 19% | 2.3% |
| Hyponatremia | 18% | 6% | 20% | 4.1% |
| Hypokalemia | 17% | 2% | 12% | 0.7% |
| Hypoalbuminemia | 14% | 0% | 57% | 3.4% |
| Hyperkalemia | 12% | 1.4% | 16% | 1.4% |
| Hypophosphatemia | 9% | 1.4% | 25% | 2.7% |
| Increased gamma glutamyl transferase | 7% | 0.7% | 39% | 4.1% |
| Hematology | | | | |
| Anemia | 62% | 7% | 36% | 0.7% |
| Lymphopenia | 14% | 1.4% | 34% | 4.1% |
| Neutropenia | 14% | 0% | 36% | 7% |

The most common lab abnormalities occurred early

Incidence of hyperbilirubinemia was higher in the ALECENSA treatment arm. However, median time to onset for elevated AST, ALT, and bilirubin levels were comparable between treatment arms and the majority of events occurred within the first 1 to 2 months^{1,2}

Based on NCI CTCAE v4.03. Excludes patients with no post-baseline lab assessments.

^aPatients with missing baseline values were included. For each laboratory abnormality, the number of patients evaluated may vary (n=131 to n=148). Please refer to PI for additional information.

ALT=alanine transaminase; AST=aspartate transaminase; CPK=creatine phosphokinase.

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.



Consistent safety profile across clinical and real-world experience¹

Primary analysis^{1,4}

| Parameter | ALECENSA (n=152) | crizotinib (n=151) |
|--------------------------------------|--|--|
| Median duration of exposure | 17.9 months (range: 0-29.0 months) | 10.7 months (range: 0-27.0 months) |
| Grade 5 ARs | 3% ^a | 5% ^b |
| Grade ≥3 ARs | 41% | 50% |
| Dose modifications due to ARs | | |
| Dose reductions | 16% | 21% |
| Dose interruptions | 19% | 25% |
| Permanent discontinuations | 11% | 13% |

^aAll unrelated to treatment.⁴

^bTwo related to treatment.⁴

Most frequent ARs (≥2%) leading to a dose modification for ALECENSA^{1,2}

- **Dose reduction:** elevated AST (3.3%), elevated ALT (2%), elevated bilirubin (2%), anemia (2%), and hyperbilirubinemia (2%)
- **Dose interruption:** ALT increased (2.6%), pneumonia (2.6%), and AST increased (2%)
- **Permanent discontinuation:** renal impairment (2%)

Real-world results

- In a real-world study, rates of dose modifications and discontinuations due to ARs for ALECENSA were comparable to the ALEX clinical trial^{11c}
 - The most common mAEs were rash (10%) and bradycardia (7.1%) in patients receiving ALECENSA
 - Rates of dose adjustments with ALECENSA were 27.1%, interruptions were 22.9%, and treatment discontinuation was 2.9%
 - The most common AEs contributing to dose adjustments were bradycardia (20.1%), rash (15.8%), and fatigue (15.8%)

^cA retrospective cohort study using electronic health record data in 117 adult patients with ALK-positive advanced NSCLC receiving ALK TKIs, with ALECENSA (n=70) or crizotinib (n=47) as the initial ALK TKI therapy.

AR=adverse reaction; mAE=major adverse event.

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.



For patients with ALK+ mNSCLC:

Dosing and administration¹

Dosing schedule

600 mg
(4 x 150 mg)



Dose reduction schedule

| Dose reduction schedule | Dose level |
|-------------------------|--|
| Starting dose | ALECENSA 600 mg taken orally twice daily |
| First dose reduction | ALECENSA 450 mg taken orally twice daily |
| Second dose reduction | ALECENSA 300 mg taken orally twice daily |


Discontinue if patients are unable to tolerate the 300 mg twice daily dose. See recommendations for dose modifications on the next page.

Administer ALECENSA until disease progression or unacceptable toxicity

- The recommended dose of ALECENSA is 600 mg orally twice daily with food
 - The recommended dose of ALECENSA in patients with severe hepatic impairment (Child-Pugh C) is 450 mg orally twice daily


- Swallow capsules whole; do not open or dissolve the contents of the capsule
- If a dose of ALECENSA is missed or vomiting occurs after taking a dose of ALECENSA, take the next dose at the scheduled time

Monitoring




Hepatotoxicity

Monitor liver function tests every 2 weeks during the first 3 months of treatment, then once a month and as clinically indicated, with more frequent testing in patients who develop transaminase and bilirubin elevations. Based on the severity of the adverse drug reaction, withhold ALECENSA and resume at a reduced dose or permanently discontinue ALECENSA



ILD/Pneumonitis

Immediately withhold ALECENSA in patients diagnosed with ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/pneumonitis have been identified




Renal Impairment

Withhold ALECENSA for severe renal impairment, then resume ALECENSA at reduced dose upon recovery, or permanently discontinue




Bradycardia

Monitor heart rate and blood pressure regularly. If symptomatic, withhold ALECENSA, then reduce dose, or permanently discontinue




Severe Myalgia and CPK Elevation

Assess CPK levels every 2 weeks for the first month of treatment and in patients reporting unexplained muscle pain, tenderness, or weakness. In case of severe CPK elevations, withhold, then resume or reduce dose



Hemolytic Anemia

If hemolytic anemia is suspected, withhold ALECENSA. If hemolytic anemia is confirmed, consider resuming at a reduced dose upon resolution or permanently discontinue



Embryo-Fetal Toxicity

ALECENSA can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception

Please see full Prescribing Information for additional guidance on monitoring.

Start your newly diagnosed ALK+ NSCLC patients on a free 30-day sample of ALECENSA.^a Contact your GNE representative OR call the Sample Accountability Call Center at (866) 736-2717.

^aDrug samples may not be sold, purchased, traded, or offered for sale, purchase, or trade, utilized to seek reimbursement, or otherwise distributed in a manner not permitted by applicable law. Samples may only be distributed to practitioners who are licensed or authorized under applicable state law to prescribe the drug product and whose practices are relevant to the FDA-approved product labeling for ALECENSA. Distribution of the sample does not obligate use or continuing use of ALECENSA. You may not advertise or otherwise use the program as a means of promoting your services or Genentech's products to patients. Genentech reserves the right to deny fulfillment of the sample to anyone deemed ineligible in accordance with stated program criteria.







GNE=Genentech; ILD=interstitial lung disease.

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.

For patients with ALK+ mNSCLC:

Dose modifications¹

Dosing modifications for adverse reactions

| Criteria | ALECENSA dose modification |
|---|---|
| ALT or AST elevation of >5X ULN <u>with</u> total bilirubin ≤2X ULN |  Temporarily withhold until recovery to baseline or to ≤3X ULN, then resume at reduced dose. See table on previous page for dose reduction schedule. |
| ALT or AST elevation >3X ULN <u>with</u> total bilirubin elevation >2X ULN in the absence of cholestasis or hemolysis |  Permanently discontinue ALECENSA. |
| Total bilirubin elevation of >3X ULN |  Temporarily withhold until recovery to baseline or to ≤1.5X ULN, then resume at reduced dose. See table on previous page for dose reduction schedule. |
| Any grade treatment-related ILD/pneumonitis |  Permanently discontinue ALECENSA. |
| Grade 3 renal impairment |  Temporarily withhold until serum creatinine recovers to ≤1.5X ULN, then resume at reduced dose. See table on previous page for dose reduction schedule. |
| Grade 4 renal impairment |  Permanently discontinue ALECENSA. |
| Symptomatic bradycardia |  Withhold ALECENSA until recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm. If contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume ALECENSA at previous dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm. If no contributing concomitant medication is identified, or if contributing concomitant medications are not discontinued or dose modified, resume ALECENSA at reduced dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm. See table on previous page for dose reduction schedule. |
| Bradycardia ^a (life-threatening consequences, urgent intervention indicated) |  Permanently discontinue ALECENSA if no contributing concomitant medication is identified. If contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume ALECENSA at reduced dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥60 bpm, with frequent monitoring as clinically indicated. Permanently discontinue ALECENSA in case of recurrence. See table on previous page for dose reduction schedule. |
| CPK elevation >5X ULN |  Temporarily withhold until recovery to baseline or to ≤2.5X ULN, then resume at same dose. |
| CPK elevation >10X ULN or second occurrence of CPK elevation of >5X ULN |  Temporarily withhold until recovery to baseline or to ≤2.5X ULN, then resume at reduced dose. See table on previous page for dose reduction schedule. |
| Hemolytic anemia |  Withhold ALECENSA if hemolytic anemia is suspected. Upon resolution, resume at reduced dose or permanently discontinue. See table on previous page for dose reduction schedule. |

^aHeart rate <60 bpm.

bpm=beats per minute; ULN=upper limit of normal.

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.



The first and only adjuvant treatment for ALK+ NSCLC (T ≥4 cm or N+):

REDUCE THE RISK OF RECURRENCE POST-RESECTION WITH A PROVEN TREATMENT APPROACH¹

DFS primary endpoint¹

ALECENSA delivered superior DFS vs chemotherapy

HR=0.24 95% CI: 0.13, 0.43; *P*<0.0001

- In the ITT population (N=257), median DFS was **not reached** for ALECENSA (95% CI: NE, NE) vs **41.3 months** (95% CI: 28.5, NE) for chemotherapy

OS secondary endpoint¹

- OS data were not mature at the time of DFS analysis with 2.3% of deaths reported overall

CNS DFS exploratory endpoint¹²

78% reduction in risk of CNS recurrence observed

- An exploratory analysis of CNS DFS comparing patients receiving ALECENSA to patients receiving chemotherapy showed an HR of 0.22 (95% CI: 0.08, 0.58) in the ITT population

ESTABLISHED SAFETY PROFILE¹

The safety observed in ALINA was generally consistent with the established ALECENSA safety profile

- The most common ARs (≥20% for all NCI CTCAE Grades) in patients treated with ALECENSA were hepatotoxicity (61%), constipation (42%), myalgia (34%), COVID-19 (29%), fatigue (25%), rash (23%), and cough (20%)
 - ARs were generally mild to moderate
- Serious ARs occurred in 13% of patients treated with ALECENSA

The efficacy and safety of ALECENSA were established in the global, open-label, Phase 3 ALINA trial. Patients with completely resected stage IB (≥4 cm) to IIIA ALK+ NSCLC were randomized to receive ALECENSA 600 mg orally twice daily (n=130) or 4 cycles of platinum-based chemotherapy (n=127). Staging was based on UICC/AJCC 7th edition. Randomization was stratified by race (Asian and other races) and stage of disease (IB, II, and IIIA). Stratification factors were applied to hazard ratio and *P*-value analysis (stratified by race in stage II-III A, stratified by race and stage in stage IB-III A). Treatment in the ALECENSA arm continued for 2 years or until disease recurrence or death due to any cause. Treatment in the chemotherapy arm continued until completion of the fourth cycle. The primary efficacy endpoint was DFS as determined by the investigator. Secondary efficacy endpoint was OS and an exploratory endpoint was time to CNS recurrence.^{1,12} AJCC=American Joint Committee on Cancer; DFS=disease-free survival; N+=node positive; UICC=Union for International Cancer Control.

Select Important Safety Information

Severe Myalgia and Creatine Phosphokinase (CPK) Elevation

- Myalgia (including muscle- and musculoskeletal-related reactions) occurred in 31% of 533 patients treated with ALECENSA, including Grade ≥3 in 0.8% of patients. Dosage modifications for myalgia events were required in 2.1% of patients
- Of the 491 with CPK laboratory data available, elevated CPK occurred in 56% of patients, including 6% Grade ≥3. The median time to Grade ≥3 CPK elevation was 15 days (interquartile range 15-337 days). Dosage modifications for elevation of CPK occurred in 5% of patients. In the ALINA study, elevated CPK occurred in 77% of 128 patients with CPK laboratory data, including 6% Grade ≥3 elevations
- Advise patients to report any unexplained muscle pain, tenderness, or weakness. Assess CPK levels every 2 weeks for the first month of treatment and as clinically indicated in patients reporting symptoms. Based on the severity of the CPK elevation, withhold ALECENSA, then resume or reduce dose

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.



ALECENSA CONSISTENTLY DELIVERED ACROSS MULTIPLE ENDPOINTS¹

SURVIVAL

Delivered superior mPFS vs crizotinib^{1ab}

- PFS by IRC: In the ITT population, mPFS was **25.7 months** for ALECENSA (95% CI: 19.9, NE) compared with 10.4 months with crizotinib (95% CI: 7.7, 14.6); (HR=0.53 [95% CI: 0.38, 0.73]; $P<0.0001$)

60% of patients who started ALECENSA were still alive at 5 years²

- In a post-hoc analysis, OS rate at year 5 was 60% with ALECENSA (n=152) vs 48% with crizotinib (n=151) (HR=0.71; [95% CI: 0.49, 1.03])

OS data were not mature at the time of primary cutoff, and the median was still not reached. This post-hoc OS analysis, conducted at ~5 years after randomization of the last patient, was exploratory in nature, and was not powered to show statistical significance.^{2,7}

RESPONSE

79% ORR with ALECENSA¹

- ORR was 79% with ALECENSA (13% CR/66% PR; 95% CI: 72, 85) vs 72% with crizotinib (6% CR/66% PR; 95% CI: 64, 79); $P=0.1652$

^aStratified by race (Asian vs non-Asian) and CNS metastases at baseline (yes vs no) for Cox model, log-rank test, and Cochran-Mantel-Haenszel test, respectively.

^bResults for PFS as determined by INV assessment (HR=0.48; 95% CI: 0.35, 0.66; $P<0.0001$) were similar to that observed by IRC.

^cClopper and Pearson exact binomial 95% CI.

^dCause-specific HR and 95% CI were estimated by Cox model where patients with competing events (systemic progression and death prior to CNS or systemic progression) were censored at the time of these events. P -values were estimated from two-sided stratified cause-specific log-rank tests.⁹

^ePatients treated is based on the PBRER report of patient exposure, which was calculated based on the global total milligram volume sales divided by the average dose per patient per year, based on US approved indications. Average dose was based on the monthly dose multiplied by treatment duration (in months). Assumption of patient exposures from the PBRER report may not necessarily correspond to a unique patient.

PBRER=Periodic Benefit-Risk Evaluation Report.

Select Important Safety Information

Hemolytic Anemia

- Hemolytic anemia was initially reported with ALECENSA in the postmarketing setting, including cases associated with a negative direct antiglobulin test (DAT) result. Assessments for the determination of hemolytic anemia were subsequently collected in the ALINA study, where hemolytic anemia was observed in 3.1% of patients treated with ALECENSA
- If hemolytic anemia is suspected, withhold ALECENSA and initiate appropriate laboratory testing. If hemolytic anemia is confirmed, consider resuming at a reduced dose upon resolution or permanently discontinue ALECENSA

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.

CNS EFFICACY

84% reduction in risk of tumors spreading or growing in the CNS at first site of progression (HR=0.16 [95%CI: 0.10, 0.28]; $P<0.0001$)^{1,2d}

- Nearly 4X more patients had CNS as the first site of progression with crizotinib than with ALECENSA (45% [n= 68/151] with crizotinib vs 12% [n=18/152] with ALECENSA)

ALECENSA delivered a durable CNS response¹

- In an exploratory subgroup analysis (IRC) of patients with measurable CNS metastasis at baseline: 81% of patients on ALECENSA achieved ORR (n=17/21; 95% CI: 58, 92) vs 50% of patients on crizotinib (n=11/22; 95% CI: 28, 72)
 - Of the patients who achieved a CNS response, 59% on ALECENSA experienced a CNS response ≥ 1 year vs 36% with crizotinib

WELL-ESTABLISHED SAFETY PROFILE

- The most common drug reactions ($\geq 20\%$ for all NCI CTCAE Grades) in patients treated with ALECENSA were constipation (34%), fatigue (26%), myalgia (23%), and edema (22%)¹
- Safety results at 5-year post-hoc analysis were consistent with the originally reported adverse events of ALECENSA in ALEX⁷
 - The most common ARs at 5 years were constipation (38.2%), anemia (27.6%), fatigue (22.4%), and increased blood bilirubin (22.4%)²

BACKED BY EXPERIENCE

ALECENSA has been used to treat ~115,000 patients with ALK+ mNSCLC worldwide^{2e}




Important Safety Information

Indications

ALECENSA is a kinase inhibitor indicated for:


- adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test
- treatment of adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test

Warnings and Precautions




Hepatotoxicity

- Severe hepatotoxicity, including drug-induced liver injury, occurred in patients treated with ALECENSA. Hepatotoxicity occurred in 41% of 533 patients treated with ALECENSA and the incidence of Grade ≥ 3 hepatotoxicity was 8%. In the ALINA study, hepatotoxicity occurred in 61% of patients treated with ALECENSA and the incidence of Grade ≥ 3 hepatotoxicity was 4.7%. The majority (72% of 136 patients) of elevated transaminases occurred during the first 3 months of treatment. Treatment discontinuation due to hepatotoxicity occurred in 3.6% of patients who received ALECENSA in the pooled safety population and 1.6% of patients treated in the ALINA study
- Concurrent elevations in alanine transaminase (ALT) or aspartate transaminase (AST) greater than or equal to 3 times the ULN and total bilirubin greater than or equal to 2 times the ULN, with normal alkaline phosphatase, occurred in less than 1% of patients treated with ALECENSA. Three patients with Grades 3-4 AST/ALT elevations had drug-induced liver injury (documented by liver biopsy in 2 cases)
- Monitor liver function tests including ALT, AST, and total bilirubin every 2 weeks during the first 3 months of treatment, then once a month and as clinically indicated, with more frequent testing in patients who develop transaminase and bilirubin elevations. Based on the severity of the adverse drug reaction, withhold ALECENSA and resume at a reduced dose, or permanently discontinue ALECENSA



Interstitial Lung Disease (ILD)/Pneumonitis

- ILD/pneumonitis occurred in 1.3% of 533 patients treated with ALECENSA with 0.4% of patients experiencing Grade 3 ILD/pneumonitis. Five patients (0.9%) discontinued ALECENSA due to ILD/pneumonitis. The median time-to-onset of Grade 3 or higher ILD/pneumonitis was 2.1 months (range: 0.6 months to 3.6 months)
- Promptly investigate for ILD/pneumonitis in any patient who presents with worsening of respiratory symptoms indicative of ILD/pneumonitis (eg, dyspnea, cough, and fever)
- Immediately withhold ALECENSA treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue ALECENSA if no other potential causes of ILD/pneumonitis have been identified



Renal Impairment

- Renal impairment occurred in 12% of 533 patients treated with ALECENSA, including Grade ≥ 3 in 1.7% of patients, of which 0.4% were fatal events
- The median time to Grade ≥ 3 renal impairment was 3.7 months (range 0.5 to 31.8 months). Dosage modifications for renal impairment were required in 2.4% of patients
- Permanently discontinue ALECENSA for Grade 4 renal toxicity. Withhold ALECENSA for Grade 3 renal toxicity until recovery to less than or equal to 1.5 times ULN, then resume at reduced dose



Bradycardia

- Symptomatic bradycardia occurred in patients treated with ALECENSA. Bradycardia occurred in 11% of 533 patients treated with ALECENSA. Twenty percent of 521 patients for whom serial electrocardiograms (ECGs) were available had post-dose heart rates of less than 50 beats per minute (bpm)
- Monitor heart rate and blood pressure regularly. For asymptomatic bradycardia, dose modification is not required. For symptomatic bradycardia that is not life-threatening, withhold ALECENSA until recovery to asymptomatic bradycardia or to a heart rate ≥ 60 bpm and evaluate concomitant medications known to cause bradycardia, as well as anti-hypertensive medications. If bradycardia is attributable to a concomitant medication, resume ALECENSA at a reduced dose upon recovery to asymptomatic bradycardia or to a heart rate of ≥ 60 bpm, with frequent monitoring as clinically indicated
- Permanently discontinue ALECENSA in cases of life-threatening bradycardia if no contributing concomitant medication is identified or for recurrence of life-threatening bradycardia


Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.



IMPORTANT
SAFETY
INFORMATION


Important Safety Information (cont'd)

Warnings and Precautions (cont'd)



Severe Myalgia and Creatine Phosphokinase (CPK) Elevation

- Severe myalgia and creatine phosphokinase (CPK) elevation occurred in patients treated with ALECENSA. Myalgia (including muscle- and musculoskeletal-related reactions) occurred in 31% of 533 patients treated with ALECENSA, including Grade ≥ 3 in 0.8% of patients. Dosage modifications for myalgia events were required in 2.1% of patients
- Of the 491 with CPK laboratory data available, elevated CPK occurred in 56% of patients, including 6% Grade ≥ 3 . The median time to Grade ≥ 3 CPK elevation was 15 days (interquartile range 15-337 days). Dosage modifications for elevation of CPK occurred in 5% of patients. In the ALINA study, elevated CPK occurred in 77% of 128 patients with CPK laboratory data, including 6% Grade ≥ 3 elevations
- Advise patients to report any unexplained muscle pain, tenderness, or weakness. Assess CPK levels every 2 weeks for the first month of treatment and as clinically indicated in patients reporting symptoms. Based on the severity of the CPK elevation, withhold ALECENSA, then resume or reduce dose



Hemolytic Anemia

- Hemolytic anemia occurred in patients treated with ALECENSA. Hemolytic anemia was initially reported with ALECENSA in the postmarketing setting, including cases associated with a negative direct antiglobulin test (DAT) result. Assessments for the determination of hemolytic anemia were subsequently collected in the ALINA study, where hemolytic anemia was observed in 3.1% of patients treated with ALECENSA
- If hemolytic anemia is suspected, withhold ALECENSA and initiate appropriate laboratory testing. If hemolytic anemia is confirmed, consider resuming at a reduced dose upon resolution or permanently discontinue ALECENSA



Embryo-Fetal Toxicity

- ALECENSA can cause fetal harm when administered to pregnant women. Administration of alectinib to pregnant rats and rabbits during the period of organogenesis resulted in embryo-fetal toxicity and abortion at maternally toxic doses with exposures approximately 2.7-fold those observed in humans with alectinib 600 mg twice daily. Advise pregnant women of the potential risk to a fetus
- Advise females of reproductive potential to use effective contraception during treatment with ALECENSA and for 5 weeks following the last dose
- Advise males with female partners of reproductive potential to use effective contraception during treatment with ALECENSA and for 3 months following the last dose



Most Common Adverse Reactions

- The most common adverse reactions ($\geq 20\%$) were hepatotoxicity (41%), constipation (39%), fatigue (36%), myalgia (31%), edema (29%), rash (23%), and cough (21%)

Use in Specific Populations



Lactation

- Because of the potential for serious adverse reactions in breastfed infants from ALECENSA, advise a lactating woman not to breastfeed during treatment with ALECENSA and for 1 week after the last dose

You may report side effects to the FDA at **1-800-FDA-1088** or www.fda.gov/medwatch. You may also report side effects to Genentech at **1-888-835-2555**.

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.



IMPORTANT
SAFETY
INFORMATION

Helping patients is a privilege

We believe every person should get the Genentech medicine they need, and we have programs to help make this happen.



You or your patients can contact us to get started.

FOR YOU AND YOUR PRACTICE

Visit [Genentech-Access.com](https://www.genentech-access.com)
or call 888-249-4918

FOR YOUR PATIENTS

Your patients can call
877-GENENTECH (877-436-3683)

An overview of our programs:

Genentech Access Solutions

Provides helpful access and reimbursement support to assist your patients and practice after a Genentech medicine is prescribed.

Genentech Patient Foundation

If patients don't have health insurance or have financial concerns and meet eligibility criteria, they may be able to get free medicine.

Co-pay Assistance Program

The Genentech Oncology Co-pay Assistance Program can help eligible patients with the out-of-pocket costs associated with ALECENSA.

Genentech Patient Resource Center

Helps patients and practices who have questions about Genentech medicines and support options.

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.



References

1. ALECENSA [prescribing information]. South San Francisco, CA: Genentech USA, Inc. 2024.
2. Data on file. Genentech, Inc.
3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed January 14, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way. See the NCCN Guidelines® for detailed recommendations.
4. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated *ALK*-positive non-small cell lung cancer. *N Engl J Med*. 2017;377(9):829-838. doi:10.1056/NEJMoa1704795
5. Camidge DR, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of the *EML4-ALK* fusion variant on the efficacy of alectinib in untreated *ALK*-positive advanced non-small cell lung cancer in the global phase III ALEX study. *J Thorac Oncol*. 2019;14(7):1233-1243. doi:10.1016/j.jtho.2019.09.004
6. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated *ALK*-positive non-small-cell lung cancer. *N Engl J Med*. 2017;377(protocol):1-384.
7. Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced *ALK*-positive non-small-cell lung cancer in the ALEX study. *Ann Oncol*. 2020;31(8):1056-1064. doi:10.1016/j.annonc.2020.04.478
8. Gadgeel S, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (*ALK*+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. *Ann Oncol*. 2018;29(11):2214-2222. doi:10.1093/annonc/mdy405
9. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated *ALK*-positive non-small-cell lung cancer. *N Engl J Med*. 2017;377(9)(suppl):1-14.
10. Dziadziuszko R, Peters S, Ruf T, et al. Clinical experience and management of adverse events in patients with advanced *ALK*-positive non-small-cell lung cancer receiving alectinib. *ESMO Open*. 2022;7(6):100612. doi:10.1016/j.esmoop.2022.100612
11. Wang M, Slatter S, Sussell J, et al. *ALK* inhibitor treatment patterns and outcomes in real-world patients with *ALK*-positive non-small-cell lung cancer: a retrospective cohort study. *Target Oncol*. 2023;18(4):571-583. doi:10.1007/s11523-023-00973-7
12. Wu Y-L, Dziadziuszko R, Ahn JS, et al; for the ALINA Investigators. Alectinib in resected *ALK*-positive non-small-cell lung cancer. *N Engl J Med*. 2024;390(14):1265-1276. doi:10.1056/NEJMoa2310532

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this presentation.



ALECENSA® and its logo are registered trademarks of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
© 2025 Genentech USA, Inc. All rights reserved. M-US-00004909(v7.0)



HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ALECENSA safely and effectively. See full prescribing information for ALECENSA.

ALECENSA® (alectinib) capsules, for oral use

Initial U.S. Approval: 2015

-----RECENT MAJOR CHANGES-----

| | |
|---|---------|
| Indications and Usage (1.1) | 04/2024 |
| Dosage and Administration (2.1, 2.2, 2.3) | 04/2024 |
| Warnings and Precautions (5) | 04/2024 |

-----INDICATIONS AND USAGE-----

ALECENSA is a kinase inhibitor indicated for:

- adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors \geq 4 cm or node positive) as detected by an FDA-approved test. (1.1)
- treatment of adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test. (1.2)

-----DOSAGE AND ADMINISTRATION-----

600 mg orally twice daily. Administer ALECENSA with food. (2.2)

-----DOSAGE FORMS AND STRENGTHS-----

Capsules: 150 mg (3)

-----CONTRAINDICATIONS-----

None. (4)

-----WARNINGS AND PRECAUTIONS-----

- Hepatotoxicity: Monitor liver laboratory tests every 2 weeks during the first 3 months of treatment, then once a month and as clinically indicated, with more frequent testing in patients who develop transaminase and bilirubin elevations. In case of severe ALT, AST, or bilirubin elevations,

withhold, then reduce dose, or permanently discontinue ALECENSA. (2.4, 5.1)

- Interstitial Lung Disease (ILD)/Pneumonitis: Immediately withhold ALECENSA in patients diagnosed with ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/pneumonitis have been identified. (2.4, 5.2)
- Renal Impairment: Withhold ALECENSA for severe renal impairment, then resume ALECENSA at reduced dose upon recovery or permanently discontinue (2.4, 5.3).
- Bradycardia: Monitor heart rate and blood pressure regularly. If symptomatic, withhold ALECENSA then reduce dose, or permanently discontinue. (2.4, 5.4)
- Severe Myalgia and Creatine Phosphokinase (CPK) Elevation: Assess CPK every 2 weeks during the first month of treatment and in patients reporting unexplained muscle pain, tenderness, or weakness. In case of severe CPK elevations, withhold, then resume or reduce dose. (2.4, 5.5)
- Hemolytic Anemia: If hemolytic anemia is suspected, withhold ALECENSA. If hemolytic anemia is confirmed, consider resuming at a reduced dose upon resolution or permanently discontinue. (5.6)
- Embryo-Fetal Toxicity: ALECENSA can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (5.7, 8.1, 8.3)

-----ADVERSE REACTIONS-----

The most common adverse reactions (incidence \geq 20%) were hepatotoxicity, constipation, fatigue, myalgia, edema, rash and cough. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

-----USE IN SPECIFIC POPULATIONS-----

Lactation: Do not breastfeed. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 04/2024

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

- 1.1 Adjuvant Treatment of Resected ALK-Positive NSCLC
- 1.2 Treatment of Metastatic ALK-Positive NSCLC

2 DOSAGE AND ADMINISTRATION

- 2.1 Patient Selection
- 2.2 Dosing and Administration
- 2.3 Recommended Dosage for Hepatic Impairment
- 2.4 Dose Modifications for Adverse Reactions

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Hepatotoxicity
- 5.2 Interstitial Lung Disease (ILD)/Pneumonitis
- 5.3 Renal Impairment
- 5.4 Bradycardia
- 5.5 Severe Myalgia and Creatine Phosphokinase (CPK) Elevation
- 5.6 Hemolytic Anemia
- 5.7 Embryo-Fetal Toxicity

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment
- 8.7 Hepatic Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

- 14.1 Adjuvant Treatment of Resected ALK-Positive NSCLC
- 14.2 Treatment of Metastatic ALK-Positive NSCLC

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Adjuvant Treatment of Resected ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

ALECENSA is indicated as adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors \geq 4 cm or node positive), as detected by an FDA-approved test [see *Dosage & Administration (2.1)*].

1.2 Treatment of Metastatic ALK-Positive NSCLC

ALECENSA is indicated for the treatment of adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test [see *Dosage & Administration (2.1)*].

2 DOSAGE AND ADMINISTRATION

2.1 Patient Selection

Select patients with resectable tumors for the adjuvant treatment of NSCLC with ALECENSA based on the presence of ALK positivity in tumor tissue [see *Indications and Usage (1.1) and Clinical Studies (14.1)*].

Select patients for the treatment of metastatic NSCLC with ALECENSA based on the presence of ALK positivity in tumor tissue or plasma specimens [see *Indications and Usage (1.2) and Clinical Studies (14.2)*]. If ALK rearrangements are not detected in a plasma specimen, test tumor tissue if feasible.

Information on FDA-approved tests for the detection of ALK rearrangements in NSCLC is available at <http://www.fda.gov/CompanionDiagnostics>.

2.2 Dosing and Administration

The recommended dosage information for ALECENSA is provided in Table 1.

Table 1: ALECENSA Recommended Dosage and Duration of Treatment

| Indication | Recommended Dosage of ALECENSA | Duration |
|--|---|---|
| Adjuvant treatment of resected NSCLC | 600 mg orally twice daily with food [see <i>Clinical Pharmacology (12.3)</i>] | For a total of 2 years or until disease recurrence or unacceptable toxicity |
| Metastatic NSCLC | | Until disease progression or unacceptable toxicity |
| <ul style="list-style-type: none">Swallow capsules whole, do not open or dissolve the contents of the capsule.If a dose of ALECENSA is missed or vomiting occurs after taking a dose of ALECENSA, take the next dose at the scheduled time. | | |

2.3 Recommended Dosage for Hepatic Impairment

The recommended dose of ALECENSA in patients with severe hepatic impairment (Child-Pugh C) is 450 mg orally twice daily [see *Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)*].

2.4 Dose Modifications for Adverse Reactions

The dose reduction schedule for ALECENSA is provided in Table 2.

Table 2: ALECENSA Dose Reduction Schedule

| Dose Reduction Schedule | Dose Level |
|-------------------------|---------------------------------|
| Starting dose | 600 mg taken orally twice daily |
| First dose reduction | 450 mg taken orally twice daily |
| Second dose reduction | 300 mg taken orally twice daily |

Discontinue if patients are unable to tolerate the 300 mg twice daily dose.

Recommendations for dose modifications of ALECENSA in case of adverse reactions are provided in Table 3.

Table 3: ALECENSA Dose Modifications for Adverse Reactions

| Criteria ^a | ALECENSA Dose Modification |
|---|---|
| ALT or AST elevation of greater than 5 times upper limit of normal (ULN) <u>with</u> total bilirubin less than or equal to 2 times ULN | Temporarily withhold until recovery to baseline or to less than or equal to 3 times ULN, then resume at reduced dose as per Table 2. |
| ALT or AST elevation greater than 3 times ULN <u>with</u> total bilirubin elevation greater than 2 times ULN in the absence of cholestasis or hemolysis | Permanently discontinue ALECENSA. |
| Total bilirubin elevation of greater than 3 times ULN | Temporarily withhold until recovery to baseline or to less than or equal to 1.5 times ULN, then resume at reduced dose as per Table 2. |
| Any grade treatment-related interstitial lung disease (ILD)/pneumonitis | Permanently discontinue ALECENSA. |
| Grade 3 renal impairment | Temporarily withhold until serum creatinine recovers to less than or equal to 1.5 times ULN, then resume at reduced dose. |
| Grade 4 renal impairment | Permanently discontinue ALECENSA. |
| Symptomatic bradycardia | Withhold ALECENSA until recovery to asymptomatic bradycardia or to a heart rate of 60 bpm or above. If contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume ALECENSA at previous dose upon recovery to asymptomatic bradycardia or to a heart rate of 60 bpm or above. If no contributing concomitant medication is identified, or if contributing concomitant medications are not discontinued or dose modified, resume ALECENSA at reduced dose (see Table 2) upon recovery to asymptomatic bradycardia or to a heart rate of 60 bpm or above. |
| Bradycardia ^b (life-threatening consequences, urgent intervention indicated) | Permanently discontinue ALECENSA if no contributing concomitant medication is identified. If contributing concomitant medication is identified and discontinued, or its dose is adjusted, resume ALECENSA at reduced dose (see Table 2) upon recovery to asymptomatic bradycardia or to a heart rate of 60 bpm or above, with |

| | |
|---|--|
| | frequent monitoring as clinically indicated. Permanently discontinue ALECENSA in case of recurrence. |
| CPK elevation greater than 5 times ULN | Temporarily withhold until recovery to baseline or to less than or equal to 2.5 times ULN, then resume at same dose. |
| CPK elevation greater than 10 times ULN or second occurrence of CPK elevation of greater than 5 times ULN | Temporarily withhold until recovery to baseline or to less than or equal to 2.5 times ULN, then resume at reduced dose as per Table 2. |
| Hemolytic Anemia | Withhold ALECENSA if hemolytic anemia is suspected. Upon resolution, resume at reduced dose or permanently discontinue. |

^a ALT = alanine transaminase; AST = aspartate transaminase; ULN = upper limit of normal; ILD = interstitial lung disease; CPK = blood creatine phosphokinase

^b Heart rate less than 60 beats per minute (bpm)

3 DOSAGE FORMS AND STRENGTHS

150 mg hard capsules, white, with “ALE” printed in black ink on the cap and “150 mg” printed in black ink on the body.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Hepatotoxicity

Severe hepatotoxicity, including drug-induced liver injury, occurred in patients treated with ALECENSA.

In the pooled safety population [see *Adverse Reactions (6.1)*] of patients who received ALECENSA, hepatotoxicity occurred in 41% of patients and the incidence of Grade ≥ 3 hepatotoxicity was 8%. In the ALINA study, hepatotoxicity occurred in 61% of patients treated with ALECENSA and the incidence of Grade ≥ 3 hepatotoxicity was 4.7%. The majority (72% of 136 patients) of elevated transaminases occurred during the first 3 months of treatment. Treatment discontinuation due to hepatotoxicity occurred in 3.6% of patients who received ALECENSA in the pooled safety population and 1.6% of patients treated in the ALINA study.

In the pooled safety population, concurrent elevations in ALT or AST greater than or equal to 3 times the ULN and total bilirubin greater than or equal to 2 times the ULN, with normal alkaline phosphatase, occurred in less than 1% of patients treated with ALECENSA. Three patients with Grades 3–4 AST/ALT elevations had drug-induced liver injury (documented by liver biopsy in two cases).

Monitor liver function tests including ALT, AST, and total bilirubin every 2 weeks during the first 3 months of treatment, then once a month and as clinically indicated, with more frequent testing in patients who develop transaminase and bilirubin elevations. Based on the severity of the adverse drug reaction, withhold ALECENSA and resume at a reduced dose or permanently discontinue ALECENSA as described in Table 3 [see *Dosage and Administration (2.4)*].

5.2 Interstitial Lung Disease (ILD)/Pneumonitis

ILD/pneumonitis occurred in patients treated with ALECENSA.

In the pooled safety population [see *Adverse Reactions (6.1)*], ILD/pneumonitis occurred in 1.3% of patients treated with ALECENSA with 0.4% of patients experiencing Grade 3 ILD/pneumonitis.

Five patients (0.9%) in the pooled safety population discontinued ALECENSA due to ILD/pneumonitis. The median time-to-onset of Grade 3 or higher ILD/pneumonitis was 2.1 months (range: 0.6 months to 3.6 months).

Promptly investigate for ILD/pneumonitis in any patient who presents with worsening of respiratory symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, and fever). Immediately withhold ALECENSA treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue ALECENSA if no other potential causes of ILD/pneumonitis have been identified [*see Dosage and Administration (2.4) and Adverse Reactions (6)*].

5.3 Renal Impairment

Renal impairment, including fatal cases, occurred in patients treated with ALECENSA.

In the pooled safety population [*see Adverse Reactions (6.1)*], renal impairment occurred in 12% of patients treated with ALECENSA, including Grade ≥ 3 in 1.7% of patients, of which 0.4% were fatal events. The median time to Grade ≥ 3 renal impairment was 3.7 months (range 0.5 to 31.8 months). Dosage modifications for renal impairment were required in 2.4% of patients.

Permanently discontinue ALECENSA for Grade 4 renal toxicity. Withhold ALECENSA for Grade 3 renal toxicity until recovery to less than or equal to 1.5 times ULN, then resume at reduced dose [*see Dosage and Administration (2.4)*].

5.4 Bradycardia

Symptomatic bradycardia occurred in patients treated with ALECENSA.

In the pooled safety population [*see Adverse Reactions (6.1)*], bradycardia occurred in 11% of patients treated with ALECENSA. Twenty percent of 521 patients treated with ALECENSA, for whom serial electrocardiograms (ECGs) were available, had post-dose heart rates of less than 50 beats per minute (bpm).

Monitor heart rate and blood pressure regularly. For asymptomatic bradycardia dose modification is not required. For symptomatic bradycardia that is not life-threatening, withhold ALECENSA until recovery to asymptomatic bradycardia or to a heart rate ≥ 60 bpm and evaluate concomitant medications known to cause bradycardia, as well as anti-hypertensive medications. If bradycardia is attributable to a concomitant medication, resume ALECENSA at a reduced dose (see Table 2) upon recovery to asymptomatic bradycardia or to a heart rate of ≥ 60 bpm, with frequent monitoring as clinically indicated.

Permanently discontinue ALECENSA in cases of life-threatening bradycardia if no contributing concomitant medication is identified [*see Dosage and Administration (2.4)*]. Permanently discontinue ALECENSA for recurrence of life-threatening bradycardia.

5.5 Severe Myalgia and Creatine Phosphokinase (CPK) Elevation

Severe myalgia and creatine phosphokinase (CPK) elevation occurred in patients treated with ALECENSA.

In the pooled safety population [*see Adverse Reactions (6.1)*], myalgia (including muscle- and musculoskeletal-related reactions) occurred in 31% of patients treated with ALECENSA, including Grade ≥ 3 in 0.8% of patients. Dosage modifications for myalgia events were required in 2.1% of patients.

In the pooled safety population, of the 491 patients with CPK laboratory data available, elevated CPK occurred in 56% of patients treated with ALECENSA, including 6% Grade ≥ 3 . The median time to Grade ≥ 3 CPK elevation was 15 days (interquartile range - 15 –337 days). Dosage modifications for elevation of CPK occurred in 5% of patients.

In the ALINA study, elevated CPK occurred in 77% of 128 patients with CPK laboratory data, including 6% Grade ≥ 3 elevations.

Advise patients to report any unexplained muscle pain, tenderness, or weakness. Assess CPK levels every 2 weeks for the first month of treatment and as clinically indicated in patients reporting symptoms. Based on the

severity of the CPK elevation, withhold ALECENSA, then resume or reduce dose [see *Dosage and Administration (2.4)*].

5.6 Hemolytic Anemia

Hemolytic anemia occurred in patients treated with ALECENSA.

Hemolytic anemia was initially reported with ALECENSA in the postmarketing setting, including cases associated with a negative direct antiglobulin test (DAT) result. Assessments for the determination of hemolytic anemia were subsequently collected in the ALINA study, where hemolytic anemia was observed in 3.1% of patients treated with ALECENSA. If hemolytic anemia is suspected, withhold ALECENSA and initiate appropriate laboratory testing. If hemolytic anemia is confirmed, consider resuming at a reduced dose upon resolution or permanently discontinue ALECENSA [see *Dosage and Administration (2.4)*].

5.7 Embryo-Fetal Toxicity

Based on findings from animal studies and its mechanism of action, ALECENSA can cause fetal harm when administered to pregnant women. Oral administration of alectinib to pregnant rats and rabbits during the period of organogenesis resulted in embryo-fetal toxicity and abortion at maternally toxic doses with exposures approximately 2.7-fold those observed in humans with alectinib 600 mg twice daily. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.

Advise females of reproductive potential to use effective contraception during treatment with ALECENSA and for 5 weeks following the last dose [see *Use in Specific Populations (8.1 and 8.3) and Clinical Pharmacology (12.1)*].

6 ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of the label:

- Hepatotoxicity [see *Warnings and Precautions (5.1)*]
- Interstitial Lung Disease (ILD)/Pneumonitis [see *Warnings and Precautions (5.2)*]
- Renal Impairment [see *Warnings and Precautions (5.3)*]
- Bradycardia [see *Warnings and Precautions (5.4)*]
- Severe Myalgia and Creatine Phosphokinase (CPK) Elevation [see *Warnings and Precautions (5.5)*]
- Hemolytic Anemia [see *Warnings and Precautions (5.6)*]
- Embryo-Fetal Toxicity [see *Warnings and Precautions (5.7)*]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to ALECENSA as a single agent at 600 mg orally twice daily in 533 patients in Studies NP28761, NP28673, ALEX and ALINA [see *Clinical Studies (14)*]. Among 533 patients who received ALECENSA, 75% were exposed for 6 months or longer and 64% were exposed for greater than one year. In this pooled safety population, the most common ($\geq 20\%$) adverse reactions were hepatotoxicity (41%), constipation (39%), fatigue (36%), myalgia (31%), edema (29%), rash (23%) and cough (21%). The most common ($\geq 2\%$) Grade 3 or 4 laboratory abnormalities were increased CPK (6%), decreased hemoglobin (4.4%), increased ALT (4.2%), increased bilirubin (4.0%) and increased AST (3.4%).

Adjuvant Treatment of Resected ALK-Positive NSCLC

The safety of ALECENSA was evaluated in ALINA, a multi-center, open-label, randomized trial for the adjuvant treatment of patients with resected ALK-positive NSCLC [see *Clinical Studies (14.1)*]. At the time of DFS analysis, the median duration of exposure was 23.9 months for ALECENSA and 2.1 months for platinum-based chemotherapy.

Serious adverse reactions occurred in 13% of patients treated with ALECENSA; the most frequent serious adverse reactions ($\geq 1\%$) were pneumonia (3.9%), appendicitis (3.1%), and acute myocardial infarction (1.6%). Permanent discontinuation of ALECENSA due to an adverse event occurred in 5% of patients; the most frequent adverse reactions ($\geq 1\%$) that led to treatment discontinuation were pneumonitis and hepatotoxicity.

Dosage interruptions of ALECENSA due to an adverse reaction occurred in 27% of patients. Adverse reactions which required dosage interruption in $\geq 2\%$ of patients included hepatotoxicity, increased blood CPK, COVID-19, myalgia, abdominal pain, and pneumonia.

Dose reductions of ALECENSA due to an adverse reaction occurred in 26% of patients. Adverse reactions which required dose reductions in $\geq 2\%$ of patients included hepatotoxicity, increased blood CPK, rash, bradycardia and myalgia.

Table 4 and 5 summarize the common adverse reactions and laboratory abnormalities observed in ALINA.

Table 4: Adverse Reactions ($\geq 10\%$) in Patients Treated with ALECENSA in ALINA

| Adverse Reaction | ALECENSA N=128 | | Chemotherapy N=120 | |
|---|-------------------|----------------|-----------------------|----------------|
| | All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) |
| Hepatobiliary System Disorders | | | | |
| Hepatotoxicity ^a | 61 | 4.7* | 13 | 0 |
| Gastrointestinal Disorders | | | | |
| Constipation | 42 | 0.8* | 25 | 0.8* |
| Abdominal pain ^b | 13 | 0 | 10 | 1.7* |
| Diarrhea ^c | 13 | 0.8* | 9 | 1.7* |
| Musculoskeletal | | | | |
| Myalgia ^d | 34 | 0.8* | 1.7 | 0 |
| Infections and Infestations | | | | |
| COVID-19 | 29 | 0 | 0.8 | 0 |
| General Disorders and Administration Site Conditions | | | | |
| Fatigue ^e | 25 | 0.8* | 28 | 4.2* |
| Edema ^f | 16 | 0 | 1.7 | 0 |
| Skin and Subcutaneous Tissue Disorders | | | | |
| Rash ^g | 23 | 1.6* | 10 | 0 |
| Respiratory System Disorders | | | | |
| Cough ^h | 20 | 0.8* | 3.3 | 0 |
| Dyspnea ⁱ | 13 | 0.8* | 2.5 | 0 |
| Renal | | | | |
| Renal Impairment ^j | 16 | 0.8* | 9 | 0 |

| Nervous System Disorders | | | | |
|---------------------------------|----|------|-----|---|
| Dysgeusia ^k | 13 | 0 | 3.3 | 0 |
| Headache | 11 | 0 | 7 | 0 |
| Investigations | | | | |
| Increased weight | 13 | 0.8* | 0.8 | 0 |
| Cardiac Disorders | | | | |
| Bradycardia ^l | 12 | 0 | 0 | 0 |

Based on NCI CTCAE v5.0

* All events are Grade 3.

^a Includes increased alanine aminotransferase, increased aspartate aminotransferase, increased bile acids, increased conjugated bilirubin, increased blood bilirubin, increased unconjugated blood bilirubin, increased gamma-glutamyltransferase, hepatotoxicity, hyperbilirubinemia, increased liver function test, ocular icterus and increased transaminases.

^b Includes abdominal discomfort, abdominal pain, lower abdominal pain, upper abdominal pain, abdominal tenderness, epigastric discomfort and gastrointestinal pain.

^c Includes colitis and diarrhea.

^d Includes muscle fatigue, muscular weakness, musculoskeletal chest pain, musculoskeletal stiffness and myalgia.

^e Includes asthenia and fatigue.

^f Includes edema, face edema, localized edema, peripheral edema, face swelling and peripheral swelling.

^g Includes acneiform dermatitis, bullous dermatitis, drug eruption, eczema, rash, erythematous rash, maculo-papular rash, papular rash, seborrheic dermatitis, urticaria and xeroderma.

^h Includes cough and productive cough.

ⁱ Includes dyspnea and exertional dyspnea.

^j Includes azotemia, increased blood creatinine, decreased renal creatinine clearance, decreased glomerular filtration rate, hypercreatininemia, renal impairment and renal failure.

^k Includes dysgeusia and taste disorder.

^l Includes bradycardia and sinus bradycardia.

Clinically significant adverse reactions in < 10% of patients who received ALECENSA in ALINA: nausea (8%), vomiting (7%), vision disorders (4.7%; includes blurred vision, visual acuity reduced and photopsia), stomatitis (4.7%; includes stomatitis and mouth ulceration), photosensitivity reaction (3.9%) and pneumonitis (2.3%).

Table 5: Worsening in Laboratory Values from Baseline Occurring in $\geq 20\%$ of Patients in Treated with ALECENSA in ALINA

| Parameter | ALECENSA N=128 | | Chemotherapy N=120 | |
|--------------------------------|-------------------|----------------|-----------------------|----------------|
| | All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) |
| Chemistry | | | | |
| Increased CPK | 77 | 8 | 8 | 1.7* |
| Increased AST | 75 | 0.8* | 25 | 0 |
| Increased bilirubin | 68 | 2.3* | 4.2 | 0 |
| Increased alkaline phosphatase | 64 | 0 | 14 | 0 |
| Increased ALT | 57 | 2.3* | 28 | 0 |
| Increased creatinine | 41 | 0 | 23 | 0 |
| Increased uric acid | 30 | 0 | 19 | 0 |
| Hematology | | | | |
| Decreased hemoglobin | 69 | 0 | 67 | 0.8* |

Based on NCI CTCAE v5.0

*All events were Grade 3

Previously Untreated Metastatic ALK-Positive NSCLC

The safety of ALECENSA was evaluated in 152 patients with ALK-positive NSCLC in the ALEX study. The median duration of exposure to ALECENSA was 17.9 months. Patient characteristics of the ALEX study population (n=303) were: median age 56 years, age less than 65 (77%), female (56%), Caucasian (50%), Asian (46%), adenocarcinoma histology (92%), never smoker (63%), and ECOG PS 0 or 1 (93%).

Serious adverse reactions occurred in 28% of patients treated with ALECENSA; serious adverse reactions reported in 2% or more of patients treated with ALECENSA were pneumonia (4.6%), and renal impairment (3.9%). Grade ≥ 3 adverse events were reported for 41% of patients in the ALECENSA arm. Fatal adverse reactions occurred in 3.3% of patients treated with ALECENSA; these were renal impairment (2 patients), sudden death, cardiac arrest, and pneumonia (1 patient each). Permanent discontinuation of ALECENSA for adverse reactions occurred in 11% of patients. Adverse drug reactions that led to discontinuation of ALECENSA in 1% or more of patients were renal impairment (2.0%), hyperbilirubinemia (1.3%), increased ALT (1.3%), and increased AST (1.3%). Dosage interruptions of ALECENSA due to an adverse reaction occurred in 20% of patients. Adverse reactions which required dosage interruption in $> 2\%$ of patients included increased ALT, pneumonia. Dose reductions of ALECENSA due to an adverse reaction occurred in 17% of patients. Adverse reactions which required dose reductions in $> 2\%$ of patients included hyperbilirubinemia, increased AST and increased ALT.

Tables 6 and 7 summarize the common adverse reactions and laboratory abnormalities observed in ALEX.

Table 6: Adverse Drug Reactions (>10% for all NCI CTCAE Grades or ≥2% for Grades 3-4) in Patients Treated with ALECENSA in ALEX

| Adverse Reaction | ALECENSA N=152 | | Crizotinib N=151 | |
|-------------------------------|-------------------|----------------|---------------------|----------------|
| | All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) |
| Gastrointestinal | | | | |
| Constipation | 34 | 0 | 33 | 0 |
| Nausea | 14 | 0.7 | 48 | 3.3 |
| Diarrhea | 12 | 0 | 45 | 2.0 |
| General | | | | |
| Fatigue ^a | 26 | 1.3 | 23 | 0.7 |
| Edema ^b | 22 | 0.7 | 34 | 0.7 |
| Musculoskeletal | | | | |
| Myalgia ^c | 23 | 0 | 4.0 | 0 |
| Skin | | | | |
| Rash ^d | 15 | 0.7 | 13 | 0 |
| Cardiac | | | | |
| Bradycardia ^e | 11 | 0 | 15 | 0 |
| Renal | | | | |
| Renal impairment ^f | 12 | 3.9* | 0 | 0 |

NCI CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SOC = System Organ Class.

^a Includes fatigue and asthenia.

^b Includes peripheral edema, edema, eyelid edema, localized edema, and face edema.

^c Includes myalgia and musculoskeletal pain.

^d Includes rash, rash maculo-papular, dermatitis acneiform, erythema, generalized rash, rash macular, rash papular, exfoliative rash, and pruritic rash.

^e Includes reported cases of bradycardia and sinus bradycardia but is not based on serial ECG assessment.

^f Includes increased blood creatinine, creatinine renal clearance decreased, glomerular filtration rate decreased, and acute kidney injury.

* Includes two Grade 5 events.

The following additional clinically significant adverse drug reactions were observed in patients treated with ALECENSA: weight gain (9.9%), vomiting (7%), photosensitivity reaction (5.3%), vision disorders (4.6%; includes blurred vision, visual impairment, vitreous floaters reduced visual acuity and diplopia), stomatitis (3.3%), dysgeusia (3.3%; includes hypogeusia), interstitial lung disease (1.3%), and drug-induced liver injury (1.3%).

Table 7: Worsening in Laboratory Values Occurring in > 10% of Patients in ALEX

| Parameter | ALECENSA N= 152 | | Crizotinib N=151 | |
|---|--------------------|-------------------|---------------------|-------------------|
| | All Grades (%) | Grades 3–4 (%) | All Grades (%) | Grades 3–4 (%) |
| Chemistry | | | | |
| Hyperbilirubinemia ^a | 54 | 5 | 4.7 | 0 |
| Increased AST ^b | 50 | 6 | 56 | 11 |
| Increased alkaline phosphatase ^c | 50 | 0 | 44 | 0 |
| Increased ALT ^c | 40 | 6 | 62 | 16 |
| Increased creatinine ^{c,d} | 38 | 4.1 | 23 | 0.7 |
| Increased CPK ^e | 37 | 2.8 | 52 | 1.4 |
| Hypocalcemia ^a | 29 | 0 | 61 | 1.4 |
| Hyperglycemia ^f | 22 | 2.2 | 19 | 2.3 |
| Hyponatremia ^g | 18 | 6 | 20 | 4.1 |
| Hypokalemia ^c | 17 | 2 | 12 | 0.7 |
| Hypoalbuminemia ^h | 14 | 0 | 57 | 3.4 |
| Hyperkalemia ^c | 12 | 1.4 | 16 | 1.4 |
| Hypophosphatemia ⁱ | 9 | 1.4 | 25 | 2.7 |
| Increased gamma glutamyl transferase ^j | 7 | 0.7 | 39 | 4.1 |
| Hematology | | | | |
| Anemia ^c | 62 | 7 | 36 | 0.7 |
| Lymphopenia ^a | 14 | 1.4 | 34 | 4.1 |
| Neutropenia ^c | 14 | 0 | 36 | 7 |

Note: Based on National Cancer Institute Common Terminology Criteria for Adverse Events v4.03.

Excludes patients with no post-baseline lab assessments.

^a n=147 for alectinib (with baseline values missing for 1 of these patients), n=148 for crizotinib.

^b n=147 for alectinib (with baseline values missing for 2 of these patients), n=148 for crizotinib.

^c n=147 for alectinib, n=148 for crizotinib.

^d Only patients with creatinine increases based on ULN definition.

^e n=143 for alectinib (with baseline values missing for 14 of these patients), n=143 for crizotinib (with baseline values missing for 13 of these patients).

^f n=134 for alectinib (with baseline values missing for 18 of these patients), n=131 for crizotinib (with baseline values missing for 8 of these patients).

^g n=147 for alectinib, n=148 for crizotinib (with baseline values missing for 1 of these patients).

^h n=146 for alectinib (with baseline values missing for 1 of these patients), n=148 for crizotinib (with baseline values missing for 1 of these patients).

ⁱ n=145 for alectinib (with baseline values missing for 2 of these patients), n=148 for crizotinib (with baseline values missing for 4 of these patients).

^j n=143 for alectinib (with baseline values missing for 4 of these patients), n=148 (with baseline values missing for 5 of these patients).

Metastatic ALK-Positive NSCLC Previously Treated with Crizotinib

The safety of ALECENSA was evaluated in 253 patients with ALK-positive non-small cell lung cancer (NSCLC) treated with ALECENSA in two clinical trials, Studies NP28761 and NP28673. The median duration of exposure to ALECENSA was 9.3 months. One hundred sixty-nine patients (67%) were exposed to ALECENSA for more than 6 months, and 100 patients (40%) for more than one year. The population characteristics were: median age 53 years, age less than 65 (86%), female (55%), White (74%), Asian (18%), NSCLC adenocarcinoma histology (96%), never or former smoker (98%), ECOG Performance Status (PS) 0 or 1 (91%), and prior chemotherapy treatment (78%).

Serious adverse reactions occurred in 19% of patients; the most frequently reported serious adverse reactions were pulmonary embolism (1.2%), dyspnea (1.2%), and hyperbilirubinemia (1.2%). Fatal adverse reactions occurred in 2.8% of patients and included hemorrhage (0.8%), intestinal perforation (0.4%), dyspnea (0.4%),

pulmonary embolism (0.4%), and endocarditis (0.4%). Permanent discontinuation of ALECENSA for adverse reactions occurred in 6% of patients. The most frequent adverse reactions that led to permanent discontinuation were hyperbilirubinemia (1.6%), increased ALT levels (1.6%), and increased AST levels (1.2%). Overall, 23% of patients initiating treatment at the recommended dose required at least one dose reduction. The median time to first dose reduction was 48 days. The most frequent adverse reactions that led to dose reductions or interruptions were elevations in bilirubin (6%), CPK (4.3%), ALT (4.0%), AST (2.8%), and vomiting (2.8%).

Tables 8 and 9 summarize the common adverse reactions and laboratory abnormalities observed in Studies NP28761 and NP28673.

Table 8: Adverse Reactions in $\geq 10\%$ (All Grades) or $\geq 2\%$ (Grades 3–4) of Patients in Studies NP28761 and NP28673

| Adverse Reactions | ALECENSA N=253 | |
|------------------------------|-------------------|------------------|
| | All Grades (%) | Grades 3–4 (%)* |
| Fatigue ^a | 41 | 1.2 |
| Constipation | 34 | 0 |
| Edema ^b | 30 | 0.8 |
| Myalgia ^c | 29 | 1.2 |
| Cough | 19 | 0 |
| Rash ^d | 18 | 0.4 |
| Nausea | 18 | 0 |
| Headache | 17 | 0.8 |
| Diarrhea | 16 | 1.2 |
| Dyspnea | 16 | 3.6 ^e |
| Back pain | 12 | 0 |
| Vomiting | 12 | 0.4 |
| Increased weight | 11 | 0.4 |
| Vision disorder ^f | 10 | 0 |

* Per Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

^a Includes fatigue and asthenia.

^b Includes peripheral edema, edema, generalized edema, eyelid edema, and periorbital edema.

^c Includes myalgia and musculoskeletal pain.

^d Includes rash, maculopapular rash, acneiform dermatitis, erythema, generalized rash, papular rash, pruritic rash, and macular rash.

^e Includes one Grade 5 event.

^f Includes blurred vision, vitreous floaters, visual impairment, reduced visual acuity, asthenopia, and diplopia.

An additional clinically significant adverse drug reaction was photosensitivity, which occurred in 9.9% of patients exposed to ALECENSA in Studies NP28761 and NP28673. Patients were advised to avoid sun exposure and to use broad-spectrum sunscreen. The incidence of Grade 2 photosensitivity was 0.4%; the remaining events were Grade 1 in severity.

Table 9: Treatment-Emergent Worsening in Laboratory Values Occurring in > 20% of Patients in Studies NP28761 and NP28673

| Parameter | ALECENSA N=250 | |
|-----------------------------------|----------------|-----------------|
| | All Grades (%) | Grades 3–4 (%)* |
| Chemistry | | |
| Increased AST | 51 | 3.6 |
| Increased Alkaline Phosphatase | 47 | 1.2 |
| Increased CPK ^a | 43 | 4.6 |
| Hyperbilirubinemia | 39 | 2.4 |
| Hyperglycemia ^b | 36 | 2.0 |
| Increased ALT | 34 | 4.8 |
| Hypocalcemia | 32 | 0.4 |
| Hypokalemia | 29 | 4.0 |
| Increased Creatinine ^c | 28 | 0 |
| Hypophosphatemia | 21 | 2.8 |
| Hyponatremia | 20 | 2.0 |
| Hematology | | |
| Anemia | 56 | 2.0 |
| Lymphopenia ^d | 22 | 4.6 |

* Per CTCAE version 4.0

^a n=218 for CPK (with baseline values missing for 91 of these patients).

^b n=152 for fasting blood glucose (with baseline values missing for 5 of these patients).

^c Only patients with creatinine increases based on ULN definition.

^d n=217 for lymphocytes (with baseline values missing for 5 of these patients).

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Based on findings from animal studies and its mechanism of action, ALECENSA can cause fetal harm when administered to a pregnant woman [see *Clinical Pharmacology (12.1)*]. There are no available data on ALECENSA use in pregnant women.

Administration of alectinib to pregnant rats and rabbits by oral gavage during the period of organogenesis resulted in embryo-fetal toxicity and abortion at maternally toxic doses with exposures approximately 2.7-fold those observed in humans treated with alectinib at 600 mg twice daily (*see Data*). Advise pregnant women of the potential risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

In a preliminary rabbit embryo-fetal study, administration of alectinib by oral gavage during the period of organogenesis resulted in abortion or complete embryo-fetal mortality at a maternally toxic dose of 27 mg/kg/day (approximately 2.9-fold the estimated area under the curve (AUC_{0-24h,ss}) in humans treated with alectinib 600 mg twice daily) in three of six pregnant rabbits. The remaining three pregnant rabbits in this group had few live fetuses, decreased fetal and placental weights, and retroesophageal subclavian artery. In a rat preliminary embryo-fetal development study, administration of alectinib during organogenesis resulted in complete litter loss in all pregnant rats at 27 mg/kg/day (approximately 4.5-fold the estimated AUC_{0-24h,ss} in humans treated with alectinib 600 mg twice daily). Doses greater than or equal to 9 mg/kg/day (approximately 2.7-fold the estimated human AUC_{0-24h,ss} in humans treated with alectinib 600 mg twice daily), resulted in maternal toxicity as well as developmental toxicities including decreased fetal weight, dilated ureter, thymic cord, small ventricle and thin ventricle wall, and reduced number of sacral and caudal vertebrae.

8.2 Lactation

Risk Summary

There are no data on the presence of alectinib or its metabolites in human milk, the effects of alectinib on the breastfed child, or its effects on milk production. Because of the potential for serious adverse reactions in breastfed children from alectinib, advise a lactating woman not to breastfeed during treatment with ALECENSA and for 1 week after the last dose.

8.3 Females and Males of Reproductive Potential

ALECENSA can cause fetal harm when administered to a pregnant woman [*see Use in Specific Populations (8.1)*].

Pregnancy Testing

Verify pregnancy status in females of reproductive potential prior to initiating ALECENSA [*see Use in Specific Populations (8.1)*].

Contraception

Females

Advise females of reproductive potential to use effective contraception during treatment with ALECENSA and for 5 weeks after the last dose [*see Use in Specific Populations (8.1)*].

Males

Based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with ALECENSA and for 3 months following the last dose [*see Nonclinical Toxicology (13.1)*].

8.4 Pediatric Use

The safety and effectiveness of ALECENSA in pediatric patients have not been established.

Animal Data

Juvenile animal studies have not been conducted using alectinib. In general toxicology studies, treatment of rats with doses of alectinib resulting in exposures greater than or equal to approximately 4.5-fold those in humans treated with alectinib at 600 mg twice daily resulted in changes in the growing teeth and bones. Findings in teeth included discoloration and changes in tooth size along with histopathological disarrangement of the

ameloblast and odontoblast layers. There were also decreases in the trabecular bone and increased osteoclast activity in the femur and sternum.

8.5 Geriatric Use

Nineteen percent of the 533 patients studied in NP28761, NP28673, ALEX and ALINA were 65 years of age and older (3.2% were 75 years of age and older). No overall differences in effectiveness were observed based on age. Exploratory analysis suggests a higher incidence of serious adverse events (38% vs 25%), more frequent adverse events leading to treatment discontinuations (18% vs 6%) and dose modifications (48% vs 35%) in patients 65 years or older as compared to those younger than 65 years.

8.6 Renal Impairment

No dose adjustment is recommended for patients with mild or moderate renal impairment. The safety of ALECENSA in patients with severe renal impairment (creatinine clearance less than 30 mL/min) or end-stage renal disease has not been studied [see *Clinical Pharmacology (12.3)*].

8.7 Hepatic Impairment


No dose adjustment is recommended for patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Increased exposure of alectinib occurred in patients with severe hepatic impairment (Child-Pugh C). The recommended dose of ALECENSA in patients with severe hepatic impairment (Child-Pugh C) is 450 mg orally twice daily [see *Dosage and Administration (2.3)* and *Clinical Pharmacology (12.3)*].

10 OVERDOSAGE

No experience with overdose is available. There is no specific antidote for overdose with ALECENSA. Alectinib and its major active metabolite M4 are > 99% bound to plasma proteins; therefore, hemodialysis is likely to be ineffective in the treatment of overdose.

11 DESCRIPTION

ALECENSA (alectinib) is a kinase inhibitor for oral administration. The molecular formula for alectinib is $C_{30}H_{34}N_4O_2 \cdot HCl$. The molecular weight is 482.62 g/mol (free base form) and 519.08 g/mol (hydrochloride salt). Alectinib is described chemically as 9-ethyl-6, 6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6, 11-dihydro-5H-benzo[*b*]carbazole-3-carbonitrile hydrochloride. The chemical structure of alectinib is shown below:



Alectinib HCl is a white to yellow white powder or powder with lumps with a pKa of 7.05 (base).

ALECENSA is supplied as hard capsules containing 150 mg of alectinib (equivalent to 161.33 mg alectinib HCl) and the following inactive ingredients: lactose monohydrate, hydroxypropylcellulose, sodium lauryl sulfate, magnesium stearate, and carboxymethylcellulose calcium. The capsule shell contains hypromellose, carrageenan, potassium chloride, titanium dioxide, corn starch, and carnauba wax. The printing ink contains red iron oxide (E172), yellow iron oxide (E172), FD&C Blue No. 2 aluminum lake (E132), carnauba wax, white shellac, and glyceryl monooleate.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Alectinib is a tyrosine kinase inhibitor that targets ALK and RET. In nonclinical studies, alectinib inhibited ALK phosphorylation and ALK-mediated activation of the downstream signaling proteins STAT3 and AKT, and decreased tumor cell viability in multiple cell lines harboring ALK fusions, amplifications, or activating mutations. The major active metabolite of alectinib, M4, showed similar in vitro potency and activity.

Alectinib and M4 demonstrated in vitro and in vivo activity against multiple mutant forms of the ALK enzyme, including some mutations identified in NSCLC tumors in patients who have progressed on crizotinib.

In mouse models implanted with tumors carrying ALK fusions, administration of alectinib resulted in antitumor activity and prolonged survival, including in mouse models implanted intracranially with ALK-driven tumor cell lines.

12.2 Pharmacodynamics

Cardiac Electrophysiology

The ability of alectinib to prolong the QT interval was assessed in 221 patients administered ALECENSA 600 mg twice daily in clinical studies. ALECENSA did not prolong the QTc (QT corrected for heart rate) interval to any clinically relevant extent. One patient had a maximum post-baseline QTcF value of greater than 500 msec, and one patient had a maximum QTcF change from baseline of greater than 60 msec.

12.3 Pharmacokinetics

The pharmacokinetics of alectinib and its major active metabolite M4 have been characterized in patients with ALK-positive NSCLC and healthy subjects.

In patients with ALK-positive NSCLC, the geometric mean (coefficient of variation %) steady-state maximal concentration ($C_{max,ss}$) for alectinib was 665 ng/mL (44%) and for M4 was 246 ng/mL (45%) with peak to trough concentration ratio of 1.2. The geometric mean steady-state area under the curve from 0 to 12 hours ($AUC_{0-12h,ss}$) for alectinib was 7,430 ng*h/mL (46%) and for M4 was 2,810 ng*h/mL (46%). Alectinib exposure is dose proportional across the dose range of 460 mg to 900 mg (i.e., 0.75 to 1.5 times the approved recommended dosage) under fed conditions. Alectinib and M4 reached steady-state concentrations by day 7. The geometric mean accumulation was approximately 6-fold for both alectinib and M4.

Absorption

Alectinib reached maximal concentrations at 4 hours following administration of ALECENSA 600 mg twice daily under fed conditions in patients with ALK-positive NSCLC.

The absolute bioavailability of alectinib was 37% (90% CI: 34%, 40%) under fed conditions.

A high-fat, high-calorie meal increased the combined exposure (AUC_{0-inf}) of alectinib plus M4 by 3.1-fold (90% CI: 2.7, 3.6) following oral administration of a single 600 mg dose of ALECENSA.

Distribution

The apparent volume of distribution is 4,016 L for alectinib and 10,093 L for M4.

Alectinib and M4 are bound to human plasma proteins greater than 99%, independent of drug concentration.

Alectinib concentrations in the cerebrospinal fluid in patients with ALK-positive NSCLC approximate estimated alectinib free concentrations in the plasma.

In vitro studies suggest that alectinib is not a substrate of P-glycoprotein (P-gp), but M4 is a substrate of P-gp. Alectinib and M4 are not substrates of breast cancer resistance protein (BCRP), organic anion-transporting polypeptide (OATP) 1B1, or OATP1B3.

Elimination

The apparent clearance (CL/F) is 81.9 L/hour for alectinib and 217 L/hour for M4. The geometric mean elimination half-life is 33 hours for alectinib and 31 hours for M4 in patients with ALK-positive NSCLC.

Metabolism

Alectinib is metabolized by CYP3A4 to its major active metabolite M4. The geometric mean metabolite/parent exposure ratio at steady-state is 0.40. M4 is subsequently metabolized by CYP3A4. Alectinib and M4 were the main circulating moieties in plasma, constituting 76% of the total radioactivity.

Excretion

Ninety-eight percent of the radioactivity was excreted in feces following oral administration of a single radiolabeled dose of alectinib under fed conditions. Eighty-four percent of the dose was excreted in the feces as unchanged alectinib, and 6% of the dose was excreted as M4. Excretion of radioactivity in urine was less than 0.5% of administered radiolabeled dose of alectinib.

Specific Populations

Age (21 to 83 years), body weight (38 to 128 kg), mild hepatic impairment (total bilirubin \leq ULN and AST $>$ ULN or total bilirubin 1 to $\leq 1.5 \times$ ULN and AST any value), mild to moderate renal impairment (creatinine clearance 30 to 89 mL/min), race (White, Asian, and Other), and sex had no clinically meaningful effect on the systemic exposure of alectinib and M4. The pharmacokinetics of alectinib have not been studied in patients with severe renal impairment (creatinine clearance $<$ 30 mL/min), or end-stage renal disease.

Hepatic Impairment: Following administration of a single oral dose of 300 mg ALECENSA, the geometric mean ratio [90% confidence interval] for the combined AUC_{inf} of alectinib and M4 in subjects with moderate hepatic impairment (Child-Pugh B) was 1.36 [0.947, 1.96] and in subjects with severe hepatic impairment (Child-Pugh C) was 1.76 [0.984, 3.15] as compared to that in subjects with normal hepatic function. The combined C_{max} of alectinib and M4 was comparable among the three groups. No dose adjustment is recommended for patients with mild or moderate hepatic impairment. The recommended dose of ALECENSA in patients with severe hepatic impairment is 450 mg orally twice daily [see *Dosage and Administration (2.3) and Use in Specific Populations (8.7)*].

Drug Interactions

Effect of Other Drugs on Alectinib

No clinically meaningful effect on the combined exposure of alectinib plus M4 was observed in clinical studies following co-administration of ALECENSA with a strong CYP3A inhibitor (posaconazole), a strong CYP3A inducer (rifampin), or an acid-reducing agent (esomeprazole).

Effect of Alectinib on Other Drugs

No clinically meaningful effect on the exposure of midazolam (sensitive CYP3A substrate) or repaglinide (sensitive CYP2C8 substrate) is expected following co-administration with ALECENSA.

In vitro studies suggest that alectinib and M4 do not inhibit CYP1A2, 2B6, 2C9, 2C19 or 2D6.

In vitro studies suggest that alectinib and M4 inhibit P-gp and BCRP. Alectinib did not inhibit OATP1B1, OATP1B3, OAT1, OAT3, or OCT2 transport activity in vitro.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity studies with alectinib have not been conducted.

Alectinib was not mutagenic in vitro in the bacterial reverse mutation (Ames) assay, but was positive with an increased number of micronuclei in a rat bone marrow micronucleus test. The mechanism of micronucleus induction was abnormal chromosome segregation (aneugenicity) and not a clastogenic effect on chromosomes.

No studies in animals have been performed to evaluate the effect of alectinib on fertility. No adverse effects on male and female reproductive organs were observed in general toxicology studies conducted in rats and monkeys.

14 CLINICAL STUDIES

14.1 Adjuvant Treatment of Resected ALK-Positive NSCLC

The efficacy of ALECENSA for the adjuvant treatment of patients with ALK-positive NSCLC following complete tumor resection was evaluated in a global, randomized open-label clinical trial (ALINA: NCT03456076). Eligible patients were required to have resectable ALK-positive NSCLC, Stage IB (tumors ≥ 4 cm) – IIIA per the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) Staging System, 7th Edition. ALK rearrangements were identified by a locally performed FDA-approved ALK test or by a centrally performed VENTANA ALK (D5F3) CDx assay.

Randomization was stratified by race (Asian vs. other races) and stage of disease (IB vs. II vs. IIIA). Patients were randomized (1:1) to receive ALECENSA 600 mg orally twice daily or platinum-based chemotherapy following tumor resection. Treatment with ALECENSA continued for a total of 2 years, or until disease recurrence or unacceptable toxicity. Platinum-based chemotherapy was administered intravenously for 4 cycles, with each cycle lasting 21 days, according to one of the following regimens:

- Cisplatin 75 mg/m² on Day 1 plus vinorelbine 25 mg/m² on Days 1 and 8
- Cisplatin 75 mg/m² on Day 1 plus gemcitabine 1250 mg/m² on Days 1 and 8
- Cisplatin 75 mg/m² on Day 1 plus pemetrexed 500 mg/m² on Day 1

In the event of intolerance to a cisplatin-based regimen, carboplatin was administered instead of cisplatin in the above combinations at a dose of AUC 5 mg/mL/min or 6 mg/mL/min.

The major efficacy outcome measures were disease-free survival (DFS) in patients with stage II-III A NSCLC and DFS in patients with stage IB-III A NSCLC (intent-to-treat [ITT] population) as assessed by investigator. DFS was defined as the time from date of randomization to the date of occurrence of any of the following: first documented recurrence of disease, new primary NSCLC, or death due to any cause, whichever occurred first. An additional efficacy outcome measure was overall survival (OS) in the ITT population.

A total of 257 patients were randomized to ALECENSA (N=130) or to chemotherapy (N=127). The median age was 56 years (range: 26 to 87), 24% were ≥ 65 years old; 52% were female; 56% were Asian, 42% were White, 0.4% were Black or African American, 2.3% were race unknown; 0.4% were Hispanic or Latino; 60% were never smokers; 53% had an ECOG PS of 0; 10% of patients had Stage IB, 35% had Stage II and 55% had Stage III A disease.

ALINA demonstrated a statistically significant improvement in DFS for patients treated with ALECENSA compared to patients treated with chemotherapy. OS data were not mature at the time of DFS analysis with 2.3% of deaths reported in the ITT population.

The efficacy results from ALINA are summarized in Table 10 and Figure 1.

Table 10: Investigator-Assessed DFS Results in ALINA

| Efficacy Parameter | Stage II-IIIa Population | | ITT Population | |
|---|--------------------------|-----------------------|-------------------|-----------------------|
| | ALECENSA N=116 | Chemotherapy N=115 | ALECENSA N=130 | Chemotherapy N=127 |
| DFS events (%) | 14 (12) | 45 (39) | 15 (12) | 50 (39) |
| Disease recurrence (%) | 14 (12) | 44 (38) | 15 (12) | 49 (38) |
| Death | 0 | 1 (0.9) | 0 | 1 (0.8) |
| Median DFS, months (95% CI) ^a | NR (NE, NE) | 44.4 (27.8, NE) | NR (NE, NE) | 41.3 (28.5, NE) |
| Hazard Ratio (95% CI) ^b | 0.24 (0.13, 0.45) | | 0.24 (0.13, 0.43) | |
| p-value ^c | <0.0001 | | <0.0001 | |


DFS = Disease-Free Survival; ITT = Intent-to-Treat; CI = Confidence Interval; NR = Not Reached; NE = Not Estimable.

^a Kaplan-Meier method.

^b Stratified Cox model, stratified by race (Asian vs. other races) in Stage II-IIIa and stratified by race (Asian vs. other races) and tumor stage (Stage IB vs. II vs. IIIa) in ITT.

^c Stratified log-rank test stratified by race (Asian vs. other races) in Stage II-IIIa and stratified by race (Asian vs. other races) and tumor stage (Stage IB vs. II vs. IIIa) in ITT.

Figure 1: Kaplan-Meier Curves of Investigator-Assessed DFS (ITT Population) in ALINA



Patients at Risk

| | | | | | | | | | | |
|--------------|-----|-----|-----|-----|----|----|----|----|----|---|
| ALECENSA | 130 | 123 | 123 | 118 | 74 | 55 | 39 | 22 | 10 | 3 |
| Chemotherapy | 127 | 112 | 98 | 89 | 55 | 41 | 27 | 18 | 11 | 2 |

In an exploratory analysis of site(s) of relapse, the proportion of patients with brain involvement at the time of disease recurrence was 4 patients (3.1%) in the ALECENSA arm and 14 patients (11%) in the chemotherapy arm.

14.2 Treatment of Metastatic ALK-Positive NSCLC

Previously Untreated Metastatic ALK-Positive NSCLC

The efficacy of ALECENSA for the treatment of patients with ALK-positive NSCLC who had not received prior systemic therapy for metastatic disease was established in an open-label, randomized, active-controlled, multicenter study (ALEX: NCT02075840). Patients were required to have an ECOG performance status of 0-2 and ALK-positive NSCLC as identified by the VENTANA ALK (D5F3) CDx assay. Neurologically stable patients with treated or untreated central nervous system (CNS) metastases, including leptomeningeal metastases, were eligible; patients with neurologic signs and symptoms due to CNS metastases were required to have completed whole brain radiation or gamma knife irradiation at least 14 days prior to enrollment and be clinically stable. Patients with a baseline QTc > 470 ms were ineligible.

Patients were randomized 1:1 to receive ALECENSA 600 mg orally twice daily or crizotinib 250 mg orally twice daily. Randomization was stratified by ECOG performance status (0/1 vs. 2), race (Asian vs. other races), and the presence or absence of CNS metastases at baseline. Treatment on both arms was continued until disease progression or unacceptable toxicity. The major efficacy outcome measure was progression-free survival (PFS) as determined by investigator assessment according to RECIST v1.1. Additional efficacy outcome measures were PFS as determined by independent review committee (IRC), time to CNS progression by IRC based on RECIST v1.1, objective response rate (ORR) and duration of response (DOR), and OS. Additional exploratory outcome measures were CNS objective response rate (CNS-ORR) and CNS duration of response (CNS-DOR) by IRC in patients with CNS metastases at baseline.

A total of 303 patients were randomized to ALECENSA (n=152) or crizotinib (n=151). The demographic characteristics of the study population were 56% female, median age 56 years (range: 18 to 91 years), 50% White, 46% Asian, 1% Black, and 3% other races. The majority of patients had adenocarcinoma (92%) and never smoked (63%). CNS metastases were present in 40% (n=122) of patients: of these, 43 patients had measurable CNS lesions as determined by an IRC. The ALEX study demonstrated a significant improvement in PFS. The time to cause-specific CNS progression as assessed by IRC was also significantly improved; there was a lower incidence of progression in the CNS as the first site of disease progression, alone or with concurrent systemic progression, in the ALECENSA arm (12%) as compared to the crizotinib arm (45%). Efficacy results from ALEX are summarized in Table 11 and Figure 2.

Table 11: Efficacy Results in ALEX per IRC Assessment


| | ALECENSA N=152 | Crizotinib N=151 |
|--|---------------------------|-----------------------------|
| Progression-Free Survival | | |
| Number of events (%) | 63 (41%) | 92 (61%) |
| Progressive disease (%) | 51 (34%) | 82 (54%) |
| Death (%) | 12 (8%) | 10 (7%) |
| Median in months (95% CI) | 25.7 (19.9, NE) | 10.4 (7.7, 14.6) |
| Hazard ratio (95% CI) ^a | 0.53 (0.38, 0.73) | |
| P-value ^b | < 0.0001 | |
| Overall Response Rate | | |
| Overall response rate, % (95% CI) ^c | 79% (72, 85) | 72% (64, 79) |
| P-value ^d | 0.1652 | |
| Complete response, % | 13% | 6% |
| Partial response, % | 66% | 66% |
| Duration of Response | | |
| Number of responders | n=120 | n=109 |
| Response duration ≥6 months | 82% | 57% |
| Response duration ≥12 months | 64% | 36% |
| Response duration ≥18 months | 37% | 14% |

CNS: central nervous system, ORR: overall response rate, IRC: independent review committee, CI: confidence interval, NE: not estimable.

^{a, b, d} Stratified by race (Asian vs. other races) and CNS metastases at baseline (yes vs. no) for Cox model, log-rank test and Cochran Mantel-Haenszel test, respectively.

^c Clopper and Pearson exact binomial 95% confidence interval.

Figure 2: Kaplan-Meier Plot of Progression-Free Survival (IRC) in ALEX



| No. at Risk | |
|-------------|----------------------------------|
| Crizotinib | 151 128 92 74 57 46 33 12 4 |
| Alectinib | 152 132 112 108 95 83 69 35 15 2 |

Results for PFS as determined by investigator assessment (HR=0.48 [95% CI: 0.35-0.66], stratified log-rank $p < 0.0001$) were similar to that observed by IRC. At the data cutoff point overall survival data was not mature.

The results of prespecified exploratory analyses of CNS response rate in patients with measurable CNS lesions at baseline are summarized in Table 12.

Table 12: IRC-Assessed CNS Responses in Patients with Measurable CNS Lesions at Baseline in ALEX

| | ALECENSA | Crizotinib |
|---|-----------------|-------------------|
| CNS Tumor Response Assessment | N = 21 | N = 22 |
| CNS Objective Response Rate, % (95% CI ^a) | 81% (58, 95) | 50% (28,72) |
| Complete Response | 38% | 5% |
| Duration of CNS Response | | |
| Number of responders | 17 | 11 |
| CNS response duration \geq 12 months | 59% | 36% |

IRC: Independent Review Committee; CI: Confidence Interval; NE: Not Estimable

^a Clopper and Pearson exact binomial 95% confidence interval

Metastatic ALK-Positive NSCLC Previously Treated with Crizotinib

The safety and efficacy of ALECENSA were established in two single-arm, multicenter clinical trials: NP28761 (NCT01588028) and NP28673 (NCT01801111). Patients with locally advanced or metastatic ALK-positive NSCLC, who have progressed on crizotinib, with documented ALK-positive NSCLC based on an FDA-approved test, and ECOG PS of 0-2 were enrolled in both studies. Eligibility criteria permitted enrollment of patients with prior chemotherapy and prior CNS radiotherapy provided that CNS metastases were stable for at least two weeks. All patients received ALECENSA 600 mg orally twice daily. The major efficacy outcome measure in both studies was objective response rate (ORR) according to Response Evaluation Criteria in Solid

Tumors (RECIST v1.1) as evaluated per Independent Review Committee (IRC). Additional outcome measures as evaluated by the IRC included duration of response (DOR), CNS ORR, and CNS DOR.

NP28761 was conducted in North America and enrolled 87 patients. Baseline demographic and disease characteristics in NP28761 were median age 54 years old (range 29 to 79, 18% 65 and over), 84% White and 8% Asian, 55% female, 35% ECOG PS 0 and 55% ECOG PS 1, 100% never or former smokers, 99% Stage IV, 94% adenocarcinoma, and 74% prior chemotherapy. The most common sites of extra-thoracic metastasis included 60% CNS (of whom 65% had received CNS radiation), 43% lymph nodes, 36% bone, and 34% liver.

NP28673 was conducted internationally and enrolled 138 patients. Baseline demographic and disease characteristics in NP28673 were median age 52 years old (range 22 to 79, 10% 65 and over), 67% White and 26% Asian, 56% female, 32% ECOG PS 0 and 59% ECOG PS 1, 98% never or former smokers, 99% Stage IV, 96% adenocarcinoma, and 80% prior chemotherapy. The most common sites of extra-thoracic metastasis included 61% CNS (of whom 73% had received CNS radiation), 51% bone, 38% lymph nodes, and 30% liver.

Efficacy results from NP28761 and NP28673 in all treated patients are summarized in Table 13. The median duration of follow-up on Study NP28761 was 4.8 months for both IRC and Investigator assessments and on Study NP28673, 10.9 months for IRC assessment and 7.0 months for Investigator assessment. All responses were partial responses.

Table 13: Efficacy Results in Studies NP28761 and NP28673

| Efficacy Parameter | NP28761 (N=87) | | NP28673 (N=138) | |
|---|-----------------------------|----------------------------|------------------------------|----------------------------|
| | IRC* Assessment | Investigator Assessment | IRC* Assessment | Investigator Assessment |
| Objective Response Rate (95% CI) | 38% (28; 49) | 46% (35; 57) | 44% (36; 53) | 48% (39; 57) |
| Number of Responders | 33 | 40 | 61 | 66 |
| Duration of Response, median in months (95% CI) | 7.5 (4.9, Not Estimable) | NE (4.9, Not Estimable) | 11.2 (9.6, Not Estimable) | 7.8 (7.4, 9.2) |

* 18 patients in NP28761 and 16 patients in NP28673 did not have measurable disease at baseline as per IRC assessment and were classified as non-responders in the IRC analysis.

An assessment of ORR and duration of response for CNS metastases in the subgroup of 51 patients in NP28761 and NP28673 with baseline measurable lesions in the CNS according to RECIST v1.1 are summarized in Table 14. Thirty-five (69%) patients with measurable CNS lesions had received prior brain radiation, including 25 (49%) who completed radiation treatment at least 6 months before starting treatment with ALECENSA.

Responses were observed irrespective of prior brain radiation status.

Table 14: CNS Objective Response in Patients with Measurable CNS Lesions in Studies NP28761 and NP28673

| Efficacy Parameter | N=51 |
|---|-----------------------------|
| CNS Objective Response Rate (95% CI) | 61% (46, 74) |
| Complete Response | 18% |
| Partial Response | 43% |
| CNS Duration of Response, median in months (95% CI) | 9.1 (5.8, Not Estimable) |

16 HOW SUPPLIED/STORAGE AND HANDLING

Hard capsules, white 150 mg capsules with “ALE” printed in black ink on the cap and “150 mg” printed in black ink on the body, available in:

240 capsules per bottle: NDC 50242-130-01

Storage and stability: Do not store above 30°C (86°F). Store in the original container to protect from light and moisture.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Inform patients of the following:

Hepatotoxicity

Inform patients of the signs and symptoms of bilirubin and hepatic transaminase elevations. Advise patients to contact their healthcare provider immediately for signs or symptoms of bilirubin and hepatic transaminase elevations [see *Warnings and Precautions (5.1)*].

Interstitial Lung Disease (ILD)/Pneumonitis

Inform patients of the risks of severe ILD/pneumonitis. Advise patients to contact their healthcare provider immediately to report new or worsening respiratory symptoms [see *Warnings and Precautions (5.2)*].

Renal Impairment

Inform patients of the risk of severe and potentially fatal renal impairment. Advise patients to contact their healthcare provider for change in urine color, reduced urine output, or swelling in the legs and feet [see *Warnings and Precautions (5.3)*].

Bradycardia

Inform patients that symptoms of bradycardia including dizziness, lightheadedness, and syncope can occur while taking ALECENSA. Advise patients to contact their healthcare provider to report these symptoms and to inform their healthcare provider about the use of any heart or blood pressure medications [see *Warnings and Precautions (5.4)*].

Severe Myalgia/CPK Elevation

Inform patients of signs and symptoms of myalgia, including unexplained and/or persistent muscle pain, tenderness, or weakness. Advise patients to contact their healthcare provider immediately to report new or worsening symptoms of muscle pain or weakness [see *Warnings and Precautions (5.5)*].

Hemolytic Anemia

Advise patients to contact their healthcare provider if they develop any signs or symptoms of hemolytic anemia [see *Warnings and Precautions (5.6)*].

Photosensitivity

Inform patients of the signs and symptoms of photosensitivity. Advise patients to avoid prolonged sun exposure while taking ALECENSA and for at least 7 days after study drug discontinuation and to use proper protection from the sun. Advise patients to use a broad spectrum ultraviolet A (UVA)/ultraviolet B (UVB) sunscreen and lip balm (SPF \geq 50) to help protect against potential sunburn [see *Adverse Reactions (6.1)*].

Embryo-Fetal Toxicity

ALECENSA can cause fetal harm if taken during pregnancy. Advise a pregnant woman and females of reproductive potential of the potential risk to a fetus [see *Warnings and Precautions (5.6) and Use in Specific Populations (8.1, 8.3)*].

Advise females of reproductive potential to use effective contraception during treatment with ALECENSA and for 5 weeks after the last dose of ALECENSA. Advise patients to inform their healthcare provider of a known or suspected pregnancy [see *Warnings and Precautions (5.6) and Use in Specific Populations (8.1, 8.3)*].

Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ALECENSA and for 3 months after the last dose [see *Use in Specific Populations (8.3) and Nonclinical Toxicology (13.1)*].

Lactation

Advise women not to breastfeed during treatment with ALECENSA and for 1 week after the last dose [see *Use in Specific Populations (8.2)*].

Administration

Instruct patients to take ALECENSA twice a day. Advise patients to take ALECENSA with food and to swallow ALECENSA capsules whole [see *Dosage and Administration (2.2)*].

Missed Dose

Advise patients that if a dose of ALECENSA is missed or if the patient vomits after taking a dose of ALECENSA, patients should be advised not to take an extra dose, but to take the next dose at the regular time [see *Dosage and Administration (2.2)*].

Distributed by:

Genentech USA, Inc.

A Member of the Roche Group

1 DNA Way

South San Francisco, CA 94080-4990

ALECENSA[®] is a registered trademark of
Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
©2024 Genentech, Inc. All rights reserved.

PATIENT INFORMATION

ALECENSA® (a-le-sen-sah)
(alectinib)
capsules

What is the most important information I should know about ALECENSA?

ALECENSA may cause serious side effects, including:

- **Liver problems (hepatotoxicity).** Liver problems are common with ALECENSA and can be severe. Your healthcare provider will do blood tests at least every 2 weeks for the first 3 months, and then 1 time each month and as needed during treatment with ALECENSA to check your liver function. **Tell your healthcare provider right away if you get any of the following signs and symptoms:**
 - feeling tired
 - feeling less hungry than usual
 - yellowing of your skin or the whites of your eyes
 - dark urine
 - itchy skin
 - nausea or vomiting
 - pain on the right side of your stomach area
 - bleeding or bruising more easily than normal
- **Lung problems.** ALECENSA may cause severe or life-threatening swelling (inflammation) of the lungs during treatment. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening symptoms, including trouble breathing, shortness of breath, cough, or fever.
- **Kidney problems.** ALECENSA may cause severe kidney problems that can lead to death. Tell your healthcare provider right away if you have a change in the amount or color of your urine, or if you get new or worsening swelling in your legs or feet.
- **Slow heartbeat (bradycardia).** ALECENSA may cause very slow heartbeats that can be severe. Your healthcare provider will check your heart rate and blood pressure during treatment with ALECENSA. Tell your healthcare provider right away if you feel dizzy, lightheaded, or if you faint during treatment with ALECENSA. Tell your healthcare provider if you take any heart or blood pressure medicines.
- **Severe muscle pain, tenderness, and weakness (myalgia).** Muscle problems are common with ALECENSA and can be severe. Your healthcare provider will do blood tests at least every 2 weeks for the first month and as needed during treatment with ALECENSA. Tell your healthcare provider right away if you get new or worsening signs and symptoms of muscle problems, including unexplained muscle pain or muscle pain that does not go away, tenderness, or weakness.
- **Breakdown of healthy red blood cells earlier than normal (hemolytic anemia).** Hemolytic anemia can happen in some people who take ALECENSA. If this happens, you may not have enough healthy red blood cells. Your healthcare provider may temporarily stop ALECENSA and do blood tests, if needed, to check for this problem. If you develop hemolytic anemia, your healthcare provider may either restart you on ALECENSA at a lower dose when the hemolytic anemia goes away, or may stop your treatment with ALECENSA. Tell your healthcare provider right away if you experience yellow skin (jaundice), weakness or dizziness, or shortness of breath.

See “What are the possible side effects of ALECENSA?” for more information about side effects.

What is ALECENSA?

ALECENSA is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene:

- to help prevent your lung cancer from coming back after your tumor has been removed by surgery (adjuvant), **or**
- as treatment when your lung cancer has spread to other parts of your body (metastatic).

Your healthcare provider will perform a test to make sure that ALECENSA is right for you.

It is not known if ALECENSA is safe and effective in children.

Before you take ALECENSA, tell your healthcare provider about all of your medical conditions, including if you:

- have liver problems
- have lung or breathing problems
- have a slow heartbeat
- are pregnant or plan to become pregnant. ALECENSA can harm your unborn baby.

Females who are able to become pregnant:

- Your healthcare provider will do a test to see if you are pregnant before starting treatment with ALECENSA.
- You should use effective birth control (contraception) during treatment with ALECENSA and for 5 weeks after the last dose of ALECENSA.
- Tell your healthcare provider right away if you become pregnant during treatment with ALECENSA or think you may be pregnant.

Males who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ALECENSA and for 3 months after the last dose of ALECENSA.

- are breastfeeding or plan to breastfeed. It is not known if ALECENSA passes into your breast milk. Do not breastfeed during treatment with ALECENSA and for 1 week after the last dose of ALECENSA. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements.

How should I take ALECENSA?

- Take ALECENSA exactly as your healthcare provider tells you to take it. Do not change your dose or stop taking ALECENSA unless your healthcare provider tells you to.
- Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with ALECENSA if you have side effects.
- Take ALECENSA 2 times a day.
- Take ALECENSA with food.
- Swallow ALECENSA capsules whole. Do not open or dissolve the capsule contents.
- If you miss a dose of ALECENSA, do not take the missed dose. Take your next dose at your regular time.
- If you vomit after taking a dose of ALECENSA, do not take an extra dose. Take your next dose at your regular time.

What should I avoid while taking ALECENSA?

Avoid spending time in the sunlight during treatment with ALECENSA and for 7 days after the last dose of ALECENSA. Your skin may be sensitive to the sun (photosensitivity) and you may burn more easily and get severe sunburns. Use sun protecting measures, such as sunscreen and lip balm with an SPF 50 or greater to help protect against sunburn.

What are the possible side effects of ALECENSA?

ALECENSA may cause serious side effects, including:

- See “What is the most important information I should know about ALECENSA?”

The most common side effects of ALECENSA include:

- constipation
- tiredness
- swelling in your hands, feet, ankles, face and eyelids
- rash
- cough

These are not all of the possible side effects of ALECENSA. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store ALECENSA?

- Do not store ALECENSA at temperatures above 86°F (30°C).
- Store ALECENSA capsules in the original container.
- Keep ALECENSA capsules dry and away from light.

Keep ALECENSA and all medicines out of the reach of children.

General information about the safe and effective use of ALECENSA.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ALECENSA for a condition for which it was not prescribed. Do not give ALECENSA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ALECENSA that is written for health professionals.

What are the ingredients in ALECENSA?

Active ingredient: alectinib

Inactive ingredients: lactose monohydrate, hydroxypropylcellulose, sodium lauryl sulfate, magnesium stearate and carboxymethylcellulose calcium. Capsule shell contains: hypromellose, carrageenan, potassium chloride, titanium dioxide, corn starch, and carnauba wax. Printing ink contains: red iron oxide (E172), yellow iron oxide (E172), FD&C Blue No. 2 aluminum lake (E132), carnauba wax, white shellac, and glyceryl monooleate.

Distributed by: Genentech, Inc., A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990

ALECENSA® is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan

© 2024 Genentech, Inc.

For more information, go to www.ALECENSA.com or call 1-800-253-2367.

This Patient Information has been approved by the U.S. Food and Drug Administration.

Revised: 04/2024